

Experiment Number: 00602-05
Test Type: CHRONIC
Route: DOSED WATER
Species/Strain: Mouse/B6C3F1/NCTR

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Test Compound: Urethane + ethanol (combination)

CAS Number: URETHCOMB

Date Report Requested: 10/18/2014

Time Report Requested: 00:10:31

First Dose M/F: NA / NA

Lab: NCTR

C Number:	C00602F
Lock Date:	Not Entered.
Cage Range:	All
Date Range:	All
Reasons For Removal:	All
Removal Date Range:	All
Treatment Groups:	All
Study Gender:	Both
PWG Approval Date	NONE

Experiment Number: 00602-05

Test Type: CHRONIC

Route: DOSED WATER

Species/Strain: Mouse/B6C3F1/NCTR

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Test Compound: Urethane + ethanol (combination)

CAS Number: URETHCOMB

Date Report Requested: 10/18/2014

Time Report Requested: 00:10:31

First Dose M/F: NA / NA

Lab: NCTR

B6C3F1/NCTR Mouse MALE	0% ETH/ 0PPM URE	0% ETH/ 10PPMURE	0% ETH/ 30PPMURE	0% ETH/ 90PPMURE	2.5%ETH/0PPM URE	2.5%ETH/10PPMUR E
Disposition Summary						
Animals Initially In Study	48	48	48	48	48	48
Early Deaths						
Moribund	2	4	3	10	9	4
Natural Death	16	13	14	22	6	10
Survivors						
Moribund		4	1	1	1	1
Natural Death	3	1	4	7		3
Terminal Sacrifice	27	26	26	8	32	30
Animals Examined Microscopically	48	48	47	48	48	48
ALIMENTARY SYSTEM						
Esophagus	(47)	(47)	(46)	(46)	(48)	(48)
Lymphoma Malignant	2 (4%)					
Gallbladder	(35)	(38)	(36)	(23)	(39)	(41)
Lymphoma Malignant			1 (3%)			
Sarcoma, Metastatic, Skin						
Intestine Large	(0)	(0)	(0)	(0)	(0)	(0)
Anus, Squamous Cell Carcinoma						
Intestine Large, Cecum	(39)	(37)	(40)	(31)	(46)	(40)
Carcinoma						
Histiocytic Sarcoma						
Lymphoma Malignant			1 (3%)			
Intestine Large, Colon	(44)	(42)	(41)	(37)	(47)	(43)
Intestine Large, Rectum	(45)	(47)	(45)	(44)	(47)	(47)
Carcinoma						
Sarcoma, Metastatic, Skin						
Intestine Small, Duodenum	(35)	(38)	(36)	(26)	(43)	(42)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 00602-05

Test Type: CHRONIC

Route: DOSED WATER

Species/Strain: Mouse/B6C3F1/NCTR

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Test Compound: Urethane + ethanol (combination)

CAS Number: URETHCOMB

Date Report Requested: 10/18/2014

Time Report Requested: 00:10:31

First Dose M/F: NA / NA

Lab: NCTR

B6C3F1/NCTR Mouse MALE	0% ETH/ 0PPM URE	0% ETH/ 10PPMURE	0% ETH/ 30PPMURE	0% ETH/ 90PPMURE	2.5%ETH/0PPM URE	2.5%ETH/10PPMUR E
Hemangioma						
Leukemia Granulocytic						
Lymphoma Malignant						
Polyp Adenomatous						
Intestine Small, Ileum	(37)	(37)	(35)	(26)	(42)	(42)
Histiocytic Sarcoma						
Lymphoma Malignant		1 (3%)	2 (6%)			1 (2%)
Intestine Small, Jejunum	(39)	(39)	(37)	(24)	(42)	(41)
Carcinoma			1 (3%)			
Histiocytic Sarcoma						1 (2%)
Leukemia Granulocytic						
Lymphoma Malignant						1 (2%)
Liver	(46)	(47)	(46)	(44)	(47)	(48)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung						
Hemangioma						
Hemangiosarcoma	1 (2%)	2 (4%)	5 (11%)	13 (30%)	3 (6%)	4 (8%)
Hepatoblastoma		1 (2%)				
Hepatocellular Adenoma	5 (11%)	10 (21%)	13 (28%)	10 (23%)	10 (21%)	13 (27%)
Hepatocellular Adenoma, Multiple	2 (4%)	3 (6%)	4 (9%)	7 (16%)	2 (4%)	2 (4%)
Hepatocellular Carcinoma	6 (13%)	6 (13%)	8 (17%)	8 (18%)	5 (11%)	3 (6%)
Hepatocellular Carcinoma, Multiple	1 (2%)		1 (2%)	1 (2%)	1 (2%)	2 (4%)
Histiocytic Sarcoma	1 (2%)	2 (4%)	5 (11%)	2 (5%)	1 (2%)	4 (8%)
Ito Cell Tumor Malignant						
Leukemia Granulocytic				1 (2%)		
Lymphoma Malignant	3 (7%)	2 (4%)	3 (7%)	1 (2%)	1 (2%)	2 (4%)
Mesothelioma Malignant, Metastatic, Pancreas					1 (2%)	

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 00602-05

Test Type: CHRONIC

Route: DOSED WATER

Species/Strain: Mouse/B6C3F1/NCTR

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Test Compound: Urethane + ethanol (combination)

CAS Number: URETHCOMB

Date Report Requested: 10/18/2014

Time Report Requested: 00:10:31

First Dose M/F: NA / NA

Lab: NCTR

B6C3F1/NCTR Mouse MALE	0% ETH/ 0PPM URE	0% ETH/ 10PPMURE	0% ETH/ 30PPMURE	0% ETH/ 90PPMURE	2.5%ETH/0PPM URE	2.5%ETH/10PPMUR E
Sarcoma, Metastatic, Skin				2 (5%)	1 (2%)	
Mesentery	(1)	(1)	(1)	(1)	(0)	(3)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung						1 (33%)
Hemangiosarcoma						
Histiocytic Sarcoma						
Lymphoma Malignant						
Mesothelioma Nos						1 (33%)
Sarcoma						
Sarcoma, Metastatic, Skin				1 (100%)		
Pancreas	(45)	(44)	(44)	(42)	(47)	(45)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung						1 (2%)
Hemangioma						
Hemangiosarcoma			1 (2%)			1 (2%)
Histiocytic Sarcoma	1 (2%)					
Leukemia Granulocytic				1 (2%)		
Lymphoma Malignant	2 (4%)	1 (2%)	2 (5%)		1 (2%)	
Mesothelioma Malignant					1 (2%)	
Mesothelioma Nos, Metastatic, Mesentery						1 (2%)
Sarcoma, Metastatic, Skin						
Salivary Glands	(47)	(48)	(46)	(46)	(48)	(48)
Leukemia Granulocytic				1 (2%)		
Lymphoma Malignant	3 (6%)	1 (2%)	3 (7%)		1 (2%)	
Neoplasm Nos, Metastatic, Thymus	1 (2%)					
Rhabdomyosarcoma, Metastatic, Skeletal Muscle						
Sarcoma, Metastatic, Skin	1 (2%)				1 (2%)	
Stomach, Forestomach	(46)	(47)	(44)	(45)	(47)	(47)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 00602-05

Test Type: CHRONIC

Route: DOSED WATER

Species/Strain: Mouse/B6C3F1/NCTR

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Test Compound: Urethane + ethanol (combination)

CAS Number: URETHCOMB

Date Report Requested: 10/18/2014

Time Report Requested: 00:10:32

First Dose M/F: NA / NA

Lab: NCTR

B6C3F1/NCTR Mouse MALE	0% ETH/ 0PPM URE	0% ETH/ 10PPMURE	0% ETH/ 30PPMURE	0% ETH/ 90PPMURE	2.5%ETH/0PPM URE	2.5%ETH/10PPMUR E
Hemangioma						
Hemangiosarcoma					1 (2%)	
Histiocytic Sarcoma						
Leukemia Granulocytic						
Lymphoma Malignant	1 (2%)					1 (2%)
Sarcoma, Metastatic, Skin						
Serosa, Hemangiosarcoma					1 (2%)	
Squamous Cell Carcinoma		1 (2%)				1 (2%)
Squamous Cell Papilloma		1 (2%)	3 (7%)		3 (7%)	4 (9%)
Stomach, Glandular	(43)	(43)	(44)		(42)	(47)
Adenoma						
Carcinoma		1 (2%)				
Leukemia Granulocytic						
Lymphoma Malignant	1 (2%)		1 (2%)			1 (2%)
Serosa, Sarcoma, Metastatic, Skin					1 (2%)	
Tongue	(47)	(48)	(47)		(48)	(47)
Lymphoma Malignant	2 (4%)					(48)
Squamous Cell Carcinoma						
CARDIOVASCULAR SYSTEM						
Blood Vessel	(47)	(46)	(47)		(45)	(48)
Lymphoma Malignant		1 (2%)				
Heart	(48)	(48)	(47)		(48)	(48)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung			1 (2%)			1 (2%)
Hemangioma		1 (2%)	1 (2%)			
Hemangiosarcoma			1 (2%)		5 (10%)	
Histiocytic Sarcoma						
Lymphoma Malignant	2 (4%)		1 (2%)			

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 00602-05

Test Type: CHRONIC

Route: DOSED WATER

Species/Strain: Mouse/B6C3F1/NCTR

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Test Compound: Urethane + ethanol (combination)

CAS Number: URETHCOMB

Date Report Requested: 10/18/2014

Time Report Requested: 00:10:32

First Dose M/F: NA / NA

Lab: NCTR

B6C3F1/NCTR Mouse MALE	0% ETH/ 0PPM URE	0% ETH/ 10PPMURE	0% ETH/ 30PPMURE	0% ETH/ 90PPMURE	2.5%ETH/0PPM URE	2.5%ETH/10PPMUR E
Lymphoma Malignant	2 (4%)		1 (2%)			
Mesothelioma Nos, Metastatic, Mesentery						1 (2%)
Neoplasm Nos, Metastatic, Thymus	1 (2%)					
Sarcoma, Metastatic, Skin						
Sarcoma, Metastatic, Thymus						
Schwannoma Malignant					1 (2%)	
ENDOCRINE SYSTEM						
Adrenal Gland	(0)	(0)	(0)	(0)	(0)	(0)
Rhabdomyosarcoma, Metastatic, Skeletal Muscle						
Adrenal Gland, Cortex	(44)	(44)	(44)	(44)	(46)	(45)
Adenoma	1 (2%)	1 (2%)			2 (4%)	1 (2%)
Histiocytic Sarcoma						
Leukemia Granulocytic						
Lymphoma Malignant			2 (5%)			
Mesothelioma Malignant, Metastatic, Pancreas					1 (2%)	
Sarcoma, Metastatic, Skin						
Subcapsular, Adenoma	1 (2%)	1 (2%)	1 (2%)		1 (2%)	
Adrenal Gland, Medulla	(44)	(43)	(42)	(43)	(44)	(42)
Bilateral, Pheochromocytoma Benign					1 (2%)	
Histiocytic Sarcoma						
Leukemia Granulocytic						
Lymphoma Malignant			1 (2%)			
Pheochromocytoma Benign			2 (5%)	5 (12%)	2 (5%)	2 (5%)
Pheochromocytoma Malignant						
Sarcoma, Metastatic, Skin						
Islets, Pancreatic	(45)	(44)	(44)	(42)	(47)	(45)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 00602-05

Test Type: CHRONIC

Route: DOSED WATER

Species/Strain: Mouse/B6C3F1/NCTR

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Test Compound: Urethane + ethanol (combination)

CAS Number: URETHCOMB

Date Report Requested: 10/18/2014

Time Report Requested: 00:10:32

First Dose M/F: NA / NA

Lab: NCTR

B6C3F1/NCTR Mouse MALE	0% ETH/ 0PPM URE	0% ETH/ 10PPMURE	0% ETH/ 30PPMURE	0% ETH/ 90PPMURE	2.5%ETH/0PPM URE	2.5%ETH/10PPMUR E
Adenoma				1 (2%)		
Carcinoma						
Leukemia Granulocytic						
Lymphoma Malignant						
Parathyroid Gland	(42)	(33)	(30)	(28)	(37)	(40)
Pituitary Gland	(35)	(42)	(39)	(38)	(46)	(42)
Lymphoma Malignant			1 (3%)			
Pars Distalis, Adenoma					1 (2%)	
Thyroid Gland	(46)	(46)	(46)	(45)	(46)	(48)
Follicular Cel, Adenoma	2 (4%)	2 (4%)			1 (2%)	2 (4%)
Lymphoma Malignant	2 (4%)		1 (2%)			
GENERAL BODY SYSTEM						
Tissue NOS	(0)	(0)	(0)	(0)	(1)	(0)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung						
Mesothelioma Malignant, Metastatic, Pancreas					1 (100%)	
GENITAL SYSTEM						
Coagulating Gland	(46)	(48)	(46)	(46)	(46)	(48)
Lymphoma Malignant	2 (4%)		1 (2%)			
Mesothelioma Nos, Metastatic, Mesentery						1 (2%)
Epididymis	(47)	(48)	(46)	(44)	(48)	(48)
Hemangioma						
Histiocytic Sarcoma						
Leukemia Granulocytic				1 (2%)		
Lymphoma Malignant	2 (4%)		1 (2%)			
Mesothelioma Malignant						

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 00602-05

Test Type: CHRONIC

Route: DOSED WATER

Species/Strain: Mouse/B6C3F1/NCTR

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Test Compound: Urethane + ethanol (combination)

CAS Number: URETHCOMB

Date Report Requested: 10/18/2014

Time Report Requested: 00:10:32

First Dose M/F: NA / NA

Lab: NCTR

B6C3F1/NCTR Mouse MALE	0% ETH/ 0PPM URE	0% ETH/ 10PPMURE	0% ETH/ 30PPMURE	0% ETH/ 90PPMURE	2.5%ETH/0PPM URE	2.5%ETH/10PPMUR E
Mesothelioma Malignant, Metastatic, Pancreas					1 (2%)	
Mesothelioma Nos, Metastatic, Mesentery						1 (2%)
Neoplasm Nos, Metastatic, Thymus	1 (2%)					
Penis	(0)	(1)	(1)	(2)	(0)	(0)
Preputial Gland	(45)	(44)	(43)	(43)	(46)	(45)
Adenoma						1 (2%)
Carcinoma			1 (2%)			
Hemangioma						
Hemangiosarcoma						
Lymphoma Malignant	1 (2%)		1 (2%)			
Sarcoma, Metastatic, Skin					1 (2%)	
Prostate	(46)	(45)	(45)	(45)	(46)	(47)
Histiocytic Sarcoma						
Leukemia Granulocytic						
Lymphoma Malignant	2 (4%)		2 (4%)			2 (4%)
Neoplasm Nos, Metastatic, Thymus	1 (2%)					
Seminal Vesicle	(46)	(48)	(46)	(46)	(47)	(48)
Adenoma						
Hemangiosarcoma						
Histiocytic Sarcoma						
Leukemia Granulocytic					1 (2%)	
Lymphoma Malignant	2 (4%)		1 (2%)			
Mesothelioma Nos, Metastatic, Mesentery						1 (2%)
Sarcoma, Metastatic, Mesentery						
Testes	(47)	(48)	(46)	(46)	(48)	(48)
Bilateral, Lipoma						
Hemangioma						

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 00602-05

Test Type: CHRONIC

Route: DOSED WATER

Species/Strain: Mouse/B6C3F1/NCTR

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Test Compound: Urethane + ethanol (combination)

CAS Number: URETHCOMB

Date Report Requested: 10/18/2014

Time Report Requested: 00:10:32

First Dose M/F: NA / NA

Lab: NCTR

B6C3F1/NCTR Mouse MALE	0% ETH/ 0PPM URE	0% ETH/ 10PPMURE	0% ETH/ 30PPMURE	0% ETH/ 90PPMURE	2.5%ETH/0PPM URE	2.5%ETH/10PPMUR E
Histiocytic Sarcoma						
Interstit Cell, Adenoma						
Lymphoma Malignant			1 (2%)	1 (2%)		
HEMATOPOIETIC SYSTEM						
Bone Marrow	(46)	(47)	(45)	(45)	(48)	(48)
Hemangiosarcoma	1 (2%)	1 (2%)				
Histiocytic Sarcoma	1 (2%)	1 (2%)		1 (2%)		1 (2%)
Leukemia Granulocytic				1 (2%)		
Lymphoma Malignant	1 (2%)		1 (2%)			
Lymph Node	(2)	(7)	(7)	(6)	(5)	(3)
Axillary, Histiocytic Sarcoma						
Axillary, Lymphoma Malignant			2 (29%)			
Axillary, Sarcoma, Metastatic, Skin	1 (50%)					
Iliac, Leukemia Granulocytic				1 (17%)		
Inguinal, Hemangiosarcoma						
Inguinal, Leukemia Granulocytic				1 (17%)		
Inguinal, Lymphoma Malignant			2 (29%)			
Lumbar, Histiocytic Sarcoma		1 (14%)				
Lumbar, Lymphoma Malignant			2 (29%)		1 (20%)	
Mediastinal, Alveolar/Bronchiolar Carcinoma, Metastatic, Lung			1 (14%)			
Mediastinal, Hepatoblastoma, Metastatic, Liver		1 (14%)				
Mediastinal, Lymphoma Malignant		1 (14%)				
Mediastinal, Sarcoma, Metastatic, Skin						1 (33%)
Pancreatic, Carcinoma, Metastatic, Stomach		1 (14%)				
Pancreatic, Lymphoma Malignant		1 (14%)				

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 00602-05

Test Type: CHRONIC

Route: DOSED WATER

Species/Strain: Mouse/B6C3F1/NCTR

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Test Compound: Urethane + ethanol (combination)

CAS Number: URETHCOMB

Date Report Requested: 10/18/2014

Time Report Requested: 00:10:32

First Dose M/F: NA / NA

Lab: NCTR

B6C3F1/NCTR Mouse MALE	0% ETH/ 0PPM URE	0% ETH/ 10PPMURE	0% ETH/ 30PPMURE	0% ETH/ 90PPMURE	2.5%ETH/0PPM URE	2.5%ETH/10PPMUR E
Renal, Alveolar/Bronchiolar Carcinoma, Metastatic, Lung						
Renal, Lymphoma Malignant		2 (29%)	3 (43%)		1 (20%)	2 (67%)
Renal, Mesothelioma Malignant, Metastatic, Pancreas					1 (20%)	
Squamous Cell Carcinoma, Metastatic, Skin						
Thoracic, Lymphoma Malignant						1 (33%)
Lymph Node, Mandibular	(46)	(46)	(46)	(45)	(48)	(48)
Carcinoma, Metastatic, Harderian Gland						
Hemangiosarcoma	1 (2%)					
Histiocytic Sarcoma						2 (4%)
Leukemia Granulocytic				1 (2%)		
Lymphoma Malignant	3 (7%)	1 (2%)	3 (7%)	1 (2%)	2 (4%)	2 (4%)
Neoplasm Nos	1 (2%)					
Sarcoma, Metastatic, Skin					1 (2%)	
Lymph Node, Mesenteric	(43)	(47)	(43)	(38)	(48)	(48)
Carcinoma, Metastatic, Harderian Gland						
Hemangiosarcoma				1 (3%)		
Histiocytic Sarcoma	1 (2%)	2 (4%)	2 (5%)	1 (3%)		4 (8%)
Leukemia Granulocytic				1 (3%)		
Lymphoma Malignant	6 (14%)	3 (6%)	5 (12%)	2 (5%)	9 (19%)	4 (8%)
Mesothelioma Malignant, Metastatic, Pancreas					1 (2%)	
Mesothelioma Nos, Metastatic, Mesentery						1 (2%)
Neoplasm Nos, Metastatic, Thymus	1 (2%)					
Sarcoma		1 (2%)				
Sarcoma, Metastatic, Skin						
Spleen	(44)	(46)	(45)	(42)	(46)	(46)
Hemangioma			1 (2%)	1 (2%)		

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 00602-05

Test Type: CHRONIC

Route: DOSED WATER

Species/Strain: Mouse/B6C3F1/NCTR

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Test Compound: Urethane + ethanol (combination)

CAS Number: URETHCOMB

Date Report Requested: 10/18/2014

Time Report Requested: 00:10:33

First Dose M/F: NA / NA

Lab: NCTR

B6C3F1/NCTR Mouse MALE	0% ETH/ 0PPM URE	0% ETH/ 10PPMURE	0% ETH/ 30PPMURE	0% ETH/ 90PPMURE	2.5%ETH/0PPM URE	2.5%ETH/10PPMURE
Hemangiosarcoma	2 (5%)	2 (4%)	2 (4%)	5 (12%)		
Histiocytic Sarcoma	1 (2%)	3 (7%)	3 (7%)	2 (5%)		3 (7%)
Leukemia Granulocytic				1 (2%)		
Lymphoma Malignant	9 (20%)	4 (9%)	5 (11%)	3 (7%)	7 (15%)	4 (9%)
Mesothelioma Malignant, Metastatic, Pancreas					1 (2%)	
Sarcoma, Metastatic, Skin						
Thymus	(32)	(29)	(35)	(27)	(35)	(32)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung			1 (3%)			1 (3%)
Leukemia Granulocytic						
Lymphoma Malignant	2 (6%)	2 (7%)	3 (9%)		1 (3%)	1 (3%)
Neoplasm Nos	1 (3%)					
Sarcoma						
Sarcoma, Metastatic, Skin				1 (4%)		
Sarcoma, Metastatic, Uncertain Primary Site	1 (3%)					
Thymoma Benign						
INTEGUMENTARY SYSTEM						
Mammary Gland	(0)	(2)	(5)	(1)	(0)	(2)
Carcinoma				1 (100%)		
Lymphoma Malignant			1 (20%)			
Skin	(47)	(48)	(47)	(48)	(48)	(48)
Basal Cell Adenoma			2 (4%)	1 (2%)		1 (2%)
Basal Cell Carcinoma		1 (2%)		1 (2%)		
Fibroma		2 (4%)	3 (6%)		2 (4%)	3 (6%)
Fibroma, Multiple	1 (2%)					
Hemangioma		1 (2%)		1 (2%)		

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 00602-05

Test Type: CHRONIC

Route: DOSED WATER

Species/Strain: Mouse/B6C3F1/NCTR

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Test Compound: Urethane + ethanol (combination)

CAS Number: URETHCOMB

Date Report Requested: 10/18/2014

Time Report Requested: 00:10:33

First Dose M/F: NA / NA

Lab: NCTR

B6C3F1/NCTR Mouse MALE	0% ETH/ 0PPM URE	0% ETH/ 10PPMURE	0% ETH/ 30PPMURE	0% ETH/ 90PPMURE	2.5%ETH/0PPM URE	2.5%ETH/10PPMURE
Hemangiosarcoma	1 (2%)			2 (4%)		
Histiocytic Sarcoma	1 (2%)		1 (2%)			
Histiocytic Sarcoma, Multiple	1 (2%)					
Lipoma				1 (2%)		
Lymphoma Malignant	1 (2%)		1 (2%)	1 (2%)	1 (2%)	
Neoplasm Nos				1 (2%)		
Osteosarcoma						
Prepuce, Fibroma						1 (2%)
Rhabdomyosarcoma, Metastatic, Skeletal Muscle		1 (2%)			1 (2%)	
Sarcoma	9 (19%)	7 (15%)	5 (11%)	9 (19%)	16 (33%)	9 (19%)
Sarcoma, Multiple	1 (2%)	2 (4%)		5 (10%)		1 (2%)
Sebaceous GI, Adenoma						
Squamous Cell Carcinoma			2 (4%)	1 (2%)		1 (2%)
Squamous Cell Papilloma		1 (2%)	1 (2%)	3 (6%)		
Squamous Cell Papilloma, Multiple				2 (4%)		
Tail, Fibroma				1 (2%)		1 (2%)
MUSCULOSKELETAL SYSTEM						
Bone	(48)	(48)	(47)	(48)	(48)	(48)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung						
Cranium, Hemangiosarcoma				1 (2%)		
Sternum, Carcinoma, Metastatic, Harderian Gland						
Sternum, Sarcoma, Metastatic, Uncertain Primary Site	1 (2%)					
Vertebra, Alveolar/Bronchiolar Carcinoma, Metastatic, Lung						
Skeletal Muscle	(48)	(48)	(47)	(48)	(48)	(48)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 00602-05

Test Type: CHRONIC

Route: DOSED WATER

Species/Strain: Mouse/B6C3F1/NCTR

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Test Compound: Urethane + ethanol (combination)

CAS Number: URETHCOMB

Date Report Requested: 10/18/2014

Time Report Requested: 00:10:33

First Dose M/F: NA / NA

Lab: NCTR

B6C3F1/NCTR Mouse MALE	0% ETH/ 0PPM URE	0% ETH/ 10PPMURE	0% ETH/ 30PPMURE	0% ETH/ 90PPMURE	2.5%ETH/0PPM URE	2.5%ETH/10PPMUR E
Alveolar/Bronchiolar Carcinoma, Metastatic				1 (2%)		
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung						1 (2%)
Diaphragm, Alveolar/Bronchiolar Carcinoma, Metastatic, Lung				1 (2%)		
Fibrosarcoma					1 (2%)	
Histiocytic Sarcoma						
Lymphoma Malignant	1 (2%)		1 (2%)			
Neoplasm Nos, Metastatic, Thymus	1 (2%)					
Rhabdomyosarcoma	1 (2%)	1 (2%)			1 (2%)	
Sarcoma				1 (2%)		
Sarcoma, Metastatic, Skin					1 (2%)	
NERVOUS SYSTEM						
Brain, Cerebellum	(48)	(47)	(44)	(46)	(47)	(48)
Lymphoma Malignant	1 (2%)		1 (2%)			
Brain, Cerebrum	(48)	(48)	(47)	(47)	(48)	(48)
Lymphoma Malignant	1 (2%)		1 (2%)			
Meninges, Leukemia Granulocytic						
Oligodendroglioma Malignant						1 (2%)
Peripheral Nerve	(47)	(48)	(47)	(48)	(48)	(48)
Schwannoma Malignant						
Spinal Cord, Thoracic	(47)	(48)	(47)	(48)	(48)	(48)
Lymphoma Malignant						
RESPIRATORY SYSTEM						
Larynx	(45)	(45)	(46)	(45)	(44)	(47)
Leukemia Granulocytic						
Lymphoma Malignant	2 (4%)					

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 00602-05

Test Type: CHRONIC

Route: DOSED WATER

Species/Strain: Mouse/B6C3F1/NCTR

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Test Compound: Urethane + ethanol (combination)

CAS Number: URETHCOMB

Date Report Requested: 10/18/2014

Time Report Requested: 00:10:33

First Dose M/F: NA / NA

Lab: NCTR

B6C3F1/NCTR Mouse MALE	0% ETH/ 0PPM URE	0% ETH/ 10PPMURE	0% ETH/ 30PPMURE	0% ETH/ 90PPMURE	2.5%ETH/0PPM URE	2.5%ETH/10PPMUR E
Lung	(48)	(48)	(47)	(48)	(48)	(48)
Alveolar/Bronchiolar Adenoma	3 (6%)	15 (31%)	15 (32%)	14 (29%)	9 (19%)	14 (29%)
Alveolar/Bronchiolar Adenoma, Multiple	1 (2%)	2 (4%)	7 (15%)	20 (42%)	1 (2%)	2 (4%)
Alveolar/Bronchiolar Carcinoma	1 (2%)	1 (2%)	8 (17%)	8 (17%)	2 (4%)	3 (6%)
Alveolar/Bronchiolar Carcinoma, Multiple			1 (2%)	1 (2%)		
Basal Cell Carcinoma, Metastatic, Skin		1 (2%)				
Carcinoma, Metastatic, Harderian Gland						
Hemangiosarcoma				1 (2%)		
Hepatoblastoma, Metastatic, Liver		1 (2%)				
Hepatocellular Carcinoma				1 (2%)		
Hepatocellular Carcinoma, Metastatic, Liver	4 (8%)		2 (4%)	1 (2%)	2 (4%)	1 (2%)
Hepatocellular Carcinoma, Multiple, Metastatic, Liver				1 (2%)		
Histiocytic Sarcoma		2 (4%)	2 (4%)	1 (2%)		2 (4%)
Leukemia Granulocytic				1 (2%)		
Lymphoma Malignant	3 (6%)		3 (6%)		1 (2%)	
Mesothelioma Malignant, Metastatic, Pancreas					1 (2%)	
Mesothelioma Nos, Metastatic, Mesentery						1 (2%)
Neoplasm Nos	1 (2%)					
Neoplasm Nos, Metastatic, Thymus	1 (2%)					
Rhabdomyosarcoma, Metastatic, Skeletal Muscle						
Sarcoma, Metastatic, Skin	1 (2%)	2 (4%)	1 (2%)	3 (6%)	1 (2%)	
Sarcoma, Metastatic, Thymus						
Schwannoma Malignant, Metastatic, Lung				1 (2%)		
Schwannoma Malignant, Metastatic, Nose		1 (2%)				
Nose	(47)	(48)	(47)	(47)	(48)	(48)
Leukemia Granulocytic						

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 00602-05

Test Type: CHRONIC

Route: DOSED WATER

Species/Strain: Mouse/B6C3F1/NCTR

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Test Compound: Urethane + ethanol (combination)

CAS Number: URETHCOMB

Date Report Requested: 10/18/2014

Time Report Requested: 00:10:33

First Dose M/F: NA / NA

Lab: NCTR

B6C3F1/NCTR Mouse MALE	0% ETH/ 0PPM URE	0% ETH/ 10PPMURE	0% ETH/ 30PPMURE	0% ETH/ 90PPMURE	2.5%ETH/0PPM URE	2.5%ETH/10PPMURE
Lymphoma Malignant	1 (2%)		1 (2%)			
Mucosa, Hemangioma				1 (2%)		
Schwannoma Malignant		1 (2%)				
Trachea	(47)	(47)	(46)	(46)	(47)	(48)
Leukemia Granulocytic						
Lymphoma Malignant	1 (2%)		1 (2%)			
SPECIAL SENSES SYSTEM						
Ear	(0)	(0)	(0)	(0)	(0)	(0)
Eye	(47)	(47)	(47)	(47)	(47)	(47)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung						1 (2%)
Leukemia Granulocytic						
Lymphoma Malignant	1 (2%)					
Schwannoma Malignant, Metastatic, Peripheral Nerve						
Harderian Gland	(47)	(47)	(47)	(47)	(48)	(48)
Adenoma	3 (6%)	10 (21%)	21 (45%)	21 (45%)	6 (13%)	13 (27%)
Bilateral, Adenoma		1 (2%)	4 (9%)	7 (15%)		1 (2%)
Bilateral, Carcinoma			1 (2%)	2 (4%)		
Carcinoma		1 (2%)	6 (13%)	14 (30%)		
Leukemia Granulocytic						
Lymphoma Malignant	2 (4%)		1 (2%)			
Lacrimal Gland	(47)	(47)	(44)	(47)	(48)	(47)
Leukemia Granulocytic				1 (2%)		
Lymphoma Malignant	2 (4%)		1 (2%)		1 (2%)	
Zymbal's Gland	(45)	(45)	(45)	(45)	(47)	(45)
Basosquamous Tumor Benign			1 (2%)			
Carcinoma						

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 00602-05
Test Type: CHRONIC
Route: DOSED WATER
Species/Strain: Mouse/B6C3F1/NCTR

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)
Test Compound: Urethane + ethanol (combination)
CAS Number: URETHCOMB

Date Report Requested: 10/18/2014
Time Report Requested: 00:10:33
First Dose M/F: NA / NA
Lab: NCTR

B6C3F1/NCTR Mouse MALE	0% ETH/ 0PPM URE	0% ETH/ 10PPMURE	0% ETH/ 30PPMURE	0% ETH/ 90PPMURE	2.5%ETH/0PPM URE	2.5%ETH/10PPMURE
Leukemia Granulocytic						
Lymphoma Malignant	2 (4%)		1 (2%)			
Sarcoma, Metastatic, Skin						
URINARY SYSTEM						
Kidney	(46)	(47)	(46)	(45)	(48)	(48)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung						1 (2%)
Hemangiosarcoma				1 (2%)		
Histiocytic Sarcoma						1 (2%)
Leukemia Granulocytic				1 (2%)		
Lymphoma Malignant	2 (4%)	2 (4%)	2 (4%)	2 (4%)	1 (2%)	1 (2%)
Mesothelioma Malignant, Metastatic, Pancreas					1 (2%)	
Renal Tubule, Adenoma			1 (2%)	1 (2%)		
Renal Tubule, Adenoma, Multiple						
Renal Tubule, Carcinoma						
Sarcoma, Metastatic, Skin						
Ureter	(0)	(0)	(0)	(0)	(0)	(0)
Urethra	(0)	(1)	(0)	(1)	(0)	(0)
Urinary Bladder	(46)	(46)	(46)	(40)	(47)	(46)
Carcinoma						
Hemangioma						
Histiocytic Sarcoma						1 (2%)
Leukemia Granulocytic						
Lymphoma Malignant	1 (2%)	1 (2%)	1 (2%)			
SYSTEMIC LESIONS						
Multiple Organ	*(48)	*(48)	*(47)	*(48)	*(48)	*(48)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 00602-05
Test Type: CHRONIC
Route: DOSED WATER
Species/Strain: Mouse/B6C3F1/NCTR

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)
Test Compound: Urethane + ethanol (combination)
CAS Number: URETHCOMB

Date Report Requested: 10/18/2014
Time Report Requested: 00:10:34
First Dose M/F: NA / NA
Lab: NCTR

B6C3F1/NCTR Mouse MALE	0% ETH/ 0PPM URE	0% ETH/ 10PPMURE	0% ETH/ 30PPMURE	0% ETH/ 90PPMURE	2.5%ETH/0PPM URE	2.5%ETH/10PPMURE
Histiocytic Sarcoma	3 (6%)	3 (6%)	6 (13%)	2 (4%)	1 (2%)	4 (8%)
Leukemia Granulocytic				1 (2%)		
Lymphoma Malignant	9 (19%)	7 (15%)	6 (13%)	4 (8%)	11 (23%)	6 (13%)
Mesothelioma Malignant					1 (2%)	
Mesothelioma Nos						1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 00602-05

Test Type: CHRONIC

Route: DOSED WATER

Species/Strain: Mouse/B6C3F1/NCTR

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Test Compound: Urethane + ethanol (combination)

CAS Number: URETHCOMB

Date Report Requested: 10/18/2014

Time Report Requested: 00:10:34

First Dose M/F: NA / NA

Lab: NCTR

B6C3F1/NCTR Mouse MALE	2.5%ETH/30PPMUR E	2.5%ETH/90PPMUR E	5.0%ETH/0PPM URE	5.0%ETH/10PPMUR E	5.0%ETH/30PPMUR E	5.0%ETH/90PPMUR E
Disposition Summary						
Animals Initially In Study	48	48	48	48	48	48
Early Deaths						
Moribund	5	6	4	3	6	11
Natural Death	14	19	4	12	15	17
Survivors						
Moribund	2	3	1	3		4
Natural Death	2	4	3	1	2	4
Terminal Sacrifice	25	16	36	29	25	12
Animals Examined Microscopically	47	48	48	48	48	48
ALIMENTARY SYSTEM						
Esophagus	(46)	(48)	(47)	(46)	(48)	(48)
Lymphoma Malignant						1 (2%)
Gallbladder	(40)	(39)	(42)	(37)	(30)	(32)
Lymphoma Malignant	1 (3%)	1 (3%)				
Sarcoma, Metastatic, Skin		1 (3%)				
Intestine Large	(0)	(0)	(0)	(0)	(2)	(2)
Anus, Squamous Cell Carcinoma						1 (50%)
Intestine Large, Cecum	(42)	(43)	(45)	(45)	(38)	(39)
Carcinoma			1 (2%)			
Histiocytic Sarcoma						1 (3%)
Lymphoma Malignant	1 (2%)					1 (3%)
Intestine Large, Colon	(44)	(46)	(47)	(45)	(43)	(43)
Intestine Large, Rectum	(47)	(47)	(47)	(46)	(48)	(46)
Carcinoma				1 (2%)		
Sarcoma, Metastatic, Skin					1 (2%)	
Intestine Small, Duodenum	(40)	(42)	(46)	(43)	(36)	(38)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 00602-05

Test Type: CHRONIC

Route: DOSED WATER

Species/Strain: Mouse/B6C3F1/NCTR

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Test Compound: Urethane + ethanol (combination)

CAS Number: URETHCOMB

Date Report Requested: 10/18/2014

Time Report Requested: 00:10:34

First Dose M/F: NA / NA

Lab: NCTR

B6C3F1/NCTR Mouse MALE	2.5%ETH/30PPMUR E	2.5%ETH/90PPMUR E	5.0%ETH/0PPM URE	5.0%ETH/10PPMUR E	5.0%ETH/30PPMUR E	5.0%ETH/90PPMUR E
Hemangioma						1 (3%)
Leukemia Granulocytic				1 (2%)		
Lymphoma Malignant	2 (5%)			1 (2%)		1 (3%)
Polyp Adenomatous		1 (2%)	1 (2%)		1 (3%)	
Intestine Small, Ileum	(41)	(41)	(42)	(43)	(36)	(39)
Histiocytic Sarcoma	1 (2%)					1 (3%)
Lymphoma Malignant	2 (5%)	1 (2%)	1 (2%)	1 (2%)	1 (3%)	4 (10%)
Intestine Small, Jejunum	(41)	(37)	(45)	(46)	(38)	(36)
Carcinoma						
Histiocytic Sarcoma						
Leukemia Granulocytic				1 (2%)		
Lymphoma Malignant	1 (2%)	1 (3%)	1 (2%)	1 (2%)	1 (3%)	1 (3%)
Liver	(46)	(48)	(48)	(46)	(48)	(48)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung		1 (2%)				
Hemangioma				2 (4%)	2 (4%)	
Hemangiosarcoma	3 (7%)	11 (23%)	2 (4%)	2 (4%)	4 (8%)	13 (27%)
Hepatoblastoma						1 (2%)
Hepatocellular Adenoma	12 (26%)	13 (27%)	17 (35%)	6 (13%)	13 (27%)	9 (19%)
Hepatocellular Adenoma, Multiple	4 (9%)	11 (23%)	2 (4%)	3 (7%)	3 (6%)	3 (6%)
Hepatocellular Carcinoma	5 (11%)	4 (8%)	7 (15%)	9 (20%)	2 (4%)	9 (19%)
Hepatocellular Carcinoma, Multiple						
Histiocytic Sarcoma	3 (7%)	6 (13%)	2 (4%)		4 (8%)	5 (10%)
Ito Cell Tumor Malignant					1 (2%)	
Leukemia Granulocytic				1 (2%)		
Lymphoma Malignant	2 (4%)	3 (6%)	1 (2%)	1 (2%)	3 (6%)	8 (17%)
Mesothelioma Malignant, Metastatic, Pancreas						

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 00602-05

Test Type: CHRONIC

Route: DOSED WATER

Species/Strain: Mouse/B6C3F1/NCTR

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Test Compound: Urethane + ethanol (combination)

CAS Number: URETHCOMB

Date Report Requested: 10/18/2014

Time Report Requested: 00:10:34

First Dose M/F: NA / NA

Lab: NCTR

B6C3F1/NCTR Mouse MALE	2.5%ETH/30PPMUR E	2.5%ETH/90PPMUR E	5.0%ETH/0PPM URE	5.0%ETH/10PPMUR E	5.0%ETH/30PPMUR E	5.0%ETH/90PPMUR E
Sarcoma, Metastatic, Skin		3 (6%)	1 (2%)		1 (2%)	
Mesentery	(2)	(3)	(4)	(1)	(2)	(0)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung						
Hemangiosarcoma			1 (25%)		1 (50%)	
Histiocytic Sarcoma	1 (50%)	1 (33%)				
Lymphoma Malignant		1 (33%)				
Mesothelioma Nos						
Sarcoma	1 (50%)					
Sarcoma, Metastatic, Skin						
Pancreas	(46)	(46)	(48)	(46)	(45)	(44)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung						
Hemangioma					1 (2%)	
Hemangiosarcoma						
Histiocytic Sarcoma		1 (2%)			1 (2%)	1 (2%)
Leukemia Granulocytic				1 (2%)		
Lymphoma Malignant	1 (2%)	2 (4%)	1 (2%)		3 (7%)	8 (18%)
Mesothelioma Malignant						
Mesothelioma Nos, Metastatic, Mesentery						
Sarcoma, Metastatic, Skin		1 (2%)				
Salivary Glands	(46)	(48)	(48)	(48)	(48)	(48)
Leukemia Granulocytic				1 (2%)		
Lymphoma Malignant	2 (4%)	2 (4%)			1 (2%)	1 (2%)
Neoplasm Nos, Metastatic, Thymus						
Rhabdomyosarcoma, Metastatic, Skeletal Muscle						1 (2%)
Sarcoma, Metastatic, Skin			1 (2%)			
Stomach, Forestomach	(46)	(46)	(48)	(47)	(45)	(48)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 00602-05

Test Type: CHRONIC

Route: DOSED WATER

Species/Strain: Mouse/B6C3F1/NCTR

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Test Compound: Urethane + ethanol (combination)

CAS Number: URETHCOMB

Date Report Requested: 10/18/2014

Time Report Requested: 00:10:34

First Dose M/F: NA / NA

Lab: NCTR

B6C3F1/NCTR Mouse MALE	2.5%ETH/30PPMUR E	2.5%ETH/90PPMUR E	5.0%ETH/0PPM URE	5.0%ETH/10PPMUR E	5.0%ETH/30PPMUR E	5.0%ETH/90PPMUR E
Hemangioma						1 (2%)
Hemangiosarcoma						
Histiocytic Sarcoma						1 (2%)
Leukemia Granulocytic				1 (2%)		
Lymphoma Malignant		1 (2%)				
Sarcoma, Metastatic, Skin		1 (2%)				
Serosa, Hemangiosarcoma						
Squamous Cell Carcinoma		2 (4%)		1 (2%)	1 (2%)	1 (2%)
Squamous Cell Papilloma	1 (2%)	2 (4%)	2 (4%)	2 (4%)	3 (7%)	5 (10%)
Stomach, Glandular	(45)	(46)	(48)	(46)	(45)	(45)
Adenoma		1 (2%)	1 (2%)			
Carcinoma						
Leukemia Granulocytic				1 (2%)		
Lymphoma Malignant		1 (2%)	1 (2%)			2 (4%)
Serosa, Sarcoma, Metastatic, Skin						
Tongue	(46)	(48)	(48)	(48)	(48)	(48)
Lymphoma Malignant		1 (2%)				1 (2%)
Squamous Cell Carcinoma				1 (2%)		1 (2%)
CARDIOVASCULAR SYSTEM						
Blood Vessel	(45)	(48)	(47)	(46)	(47)	(47)
Lymphoma Malignant						1 (2%)
Heart	(47)	(48)	(47)	(48)	(48)	(48)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung		1 (2%)				2 (4%)
Hemangioma						
Hemangiosarcoma	2 (4%)	4 (8%)			1 (2%)	4 (8%)
Histiocytic Sarcoma			1 (2%)		1 (2%)	1 (2%)
Lymphoma Malignant		1 (2%)	1 (2%)			4 (8%)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 00602-05

Test Type: CHRONIC

Route: DOSED WATER

Species/Strain: Mouse/B6C3F1/NCTR

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Test Compound: Urethane + ethanol (combination)

CAS Number: URETHCOMB

Date Report Requested: 10/18/2014

Time Report Requested: 00:10:34

First Dose M/F: NA / NA

Lab: NCTR

B6C3F1/NCTR Mouse MALE	2.5%ETH/30PPMUR E	2.5%ETH/90PPMUR E	5.0%ETH/0PPM URE	5.0%ETH/10PPMUR E	5.0%ETH/30PPMUR E	5.0%ETH/90PPMUR E
Lymphoma Malignant		1 (2%)		1 (2%)		4 (8%)
Mesothelioma Nos, Metastatic, Mesentery						
Neoplasm Nos, Metastatic, Thymus						
Sarcoma, Metastatic, Skin		1 (2%)				
Sarcoma, Metastatic, Thymus						1 (2%)
Schwannoma Malignant						
ENDOCRINE SYSTEM						
Adrenal Gland	(0)	(0)	(0)	(0)	(0)	(1)
Rhabdomyosarcoma, Metastatic, Skeletal Muscle						1 (100%)
Adrenal Gland, Cortex	(46)	(46)	(46)	(47)	(47)	(45)
Adenoma			2 (4%)	3 (6%)	1 (2%)	
Histiocytic Sarcoma	1 (2%)					
Leukemia Granulocytic				1 (2%)		
Lymphoma Malignant		1 (2%)			1 (2%)	
Mesothelioma Malignant, Metastatic, Pancreas						
Sarcoma, Metastatic, Skin		1 (2%)				
Subcapsular, Adenoma	1 (2%)		1 (2%)			
Adrenal Gland, Medulla	(45)	(46)	(46)	(46)	(46)	(45)
Bilateral, Pheochromocytoma Benign		1 (2%)				
Histiocytic Sarcoma	1 (2%)					
Leukemia Granulocytic				1 (2%)		
Lymphoma Malignant					1 (2%)	
Pheochromocytoma Benign	2 (4%)	3 (7%)	2 (4%)	6 (13%)	3 (7%)	2 (4%)
Pheochromocytoma Malignant						1 (2%)
Sarcoma, Metastatic, Skin		1 (2%)				
Islets, Pancreatic	(46)	(46)	(48)	(46)	(46)	(44)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 00602-05

Test Type: CHRONIC

Route: DOSED WATER

Species/Strain: Mouse/B6C3F1/NCTR

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Test Compound: Urethane + ethanol (combination)

CAS Number: URETHCOMB

Date Report Requested: 10/18/2014

Time Report Requested: 00:10:34

First Dose M/F: NA / NA

Lab: NCTR

B6C3F1/NCTR Mouse MALE	2.5%ETH/30PPMUR E	2.5%ETH/90PPMUR E	5.0%ETH/0PPM URE	5.0%ETH/10PPMUR E	5.0%ETH/30PPMUR E	5.0%ETH/90PPMUR E
Adenoma		2 (4%)		1 (2%)		
Carcinoma						1 (2%)
Leukemia Granulocytic				1 (2%)		
Lymphoma Malignant		1 (2%)				1 (2%)
Parathyroid Gland	(43)	(38)	(38)	(38)	(41)	(37)
Pituitary Gland	(41)	(42)	(39)	(39)	(42)	(42)
Lymphoma Malignant						1 (2%)
Pars Distalis, Adenoma						
Thyroid Gland	(46)	(47)	(45)	(47)	(48)	(47)
Follicular Cel, Adenoma	1 (2%)	2 (4%)	1 (2%)			
Lymphoma Malignant		1 (2%)				3 (6%)
GENERAL BODY SYSTEM						
Tissue NOS	(0)	(0)	(0)	(0)	(0)	(1)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung						1 (100%)
Mesothelioma Malignant, Metastatic, Pancreas						
GENITAL SYSTEM						
Coagulating Gland	(45)	(46)	(47)	(47)	(48)	(44)
Lymphoma Malignant	1 (2%)	2 (4%)				2 (5%)
Mesothelioma Nos, Metastatic, Mesentery						
Epididymis	(46)	(48)	(48)	(48)	(48)	(47)
Hemangioma	1 (2%)	1 (2%)				
Histiocytic Sarcoma	1 (2%)	1 (2%)			1 (2%)	1 (2%)
Leukemia Granulocytic				1 (2%)		
Lymphoma Malignant	1 (2%)	3 (6%)				5 (11%)
Mesothelioma Malignant	1 (2%)					

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 00602-05

Test Type: CHRONIC

Route: DOSED WATER

Species/Strain: Mouse/B6C3F1/NCTR

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Test Compound: Urethane + ethanol (combination)

CAS Number: URETHCOMB

Date Report Requested: 10/18/2014

Time Report Requested: 00:10:35

First Dose M/F: NA / NA

Lab: NCTR

B6C3F1/NCTR Mouse MALE	2.5%ETH/30PPMUR E	2.5%ETH/90PPMUR E	5.0%ETH/0PPM URE	5.0%ETH/10PPMUR E	5.0%ETH/30PPMUR E	5.0%ETH/90PPMUR E
Mesothelioma Malignant, Metastatic, Pancreas						
Mesothelioma Nos, Metastatic, Mesentery						
Neoplasm Nos, Metastatic, Thymus						
Penis	(2)	(2)	(0)	(0)	(2)	(0)
Preputial Gland	(45)	(46)	(45)	(46)	(45)	(44)
Adenoma						
Carcinoma						
Hemangioma	1 (2%)	3 (7%)			1 (2%)	
Hemangiosarcoma	1 (2%)	1 (2%)				
Lymphoma Malignant	1 (2%)	1 (2%)				1 (2%)
Sarcoma, Metastatic, Skin						
Prostate	(43)	(48)	(46)	(46)	(45)	(48)
Histiocytic Sarcoma		1 (2%)				
Leukemia Granulocytic				1 (2%)		
Lymphoma Malignant	1 (2%)	2 (4%)	1 (2%)		2 (4%)	6 (13%)
Neoplasm Nos, Metastatic, Thymus						
Seminal Vesicle	(46)	(47)	(47)	(47)	(48)	(45)
Adenoma					1 (2%)	
Hemangiosarcoma		1 (2%)				
Histiocytic Sarcoma		1 (2%)				1 (2%)
Leukemia Granulocytic				1 (2%)		
Lymphoma Malignant	2 (4%)	2 (4%)				3 (7%)
Mesothelioma Nos, Metastatic, Mesentery						
Sarcoma, Metastatic, Mesentery	1 (2%)					
Testes	(47)	(47)	(48)	(48)	(48)	(48)
Bilateral, Lipoma	1 (2%)					
Hemangioma			1 (2%)			

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 00602-05
Test Type: CHRONIC
Route: DOSED WATER
Species/Strain: Mouse/B6C3F1/NCTR

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)
Test Compound: Urethane + ethanol (combination)
CAS Number: URETHCOMB

Date Report Requested: 10/18/2014
Time Report Requested: 00:10:35
First Dose M/F: NA / NA
Lab: NCTR

B6C3F1/NCTR Mouse MALE	2.5%ETH/30PPMUR E	2.5%ETH/90PPMUR E	5.0%ETH/0PPM URE	5.0%ETH/10PPMUR E	5.0%ETH/30PPMUR E	5.0%ETH/90PPMUR E
Histiocytic Sarcoma		1 (2%)				
Interstit Cell, Adenoma				1 (2%)		
Lymphoma Malignant						
HEMATOPOIETIC SYSTEM						
Bone Marrow	(47)	(46)	(48)	(46)	(46)	(46)
Hemangiosarcoma				1 (2%)		
Histiocytic Sarcoma	2 (4%)				1 (2%)	2 (4%)
Leukemia Granulocytic				1 (2%)		
Lymphoma Malignant	1 (2%)	2 (4%)				4 (9%)
Lymph Node	(4)	(6)	(2)	(3)	(6)	(10)
Axillary, Histiocytic Sarcoma			1 (50%)			
Axillary, Lymphoma Malignant	1 (25%)				1 (17%)	2 (20%)
Axillary, Sarcoma, Metastatic, Skin		1 (17%)				
Iliac, Leukemia Granulocytic						
Inguinal, Hemangiosarcoma		1 (17%)				
Inguinal, Leukemia Granulocytic						
Inguinal, Lymphoma Malignant	2 (50%)	2 (33%)		1 (33%)	1 (17%)	4 (40%)
Lumbar, Histiocytic Sarcoma					1 (17%)	1 (10%)
Lumbar, Lymphoma Malignant	1 (25%)	1 (17%)			2 (33%)	1 (10%)
Mediastinal, Alveolar/Bronchiolar Carcinoma, Metastatic, Lung						
Mediastinal, Hepatoblastoma, Metastatic, Liver						
Mediastinal, Lymphoma Malignant						
Mediastinal, Sarcoma, Metastatic, Skin						
Pancreatic, Carcinoma, Metastatic, Stomach						
Pancreatic, Lymphoma Malignant						1 (10%)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 00602-05

Test Type: CHRONIC

Route: DOSED WATER

Species/Strain: Mouse/B6C3F1/NCTR

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Test Compound: Urethane + ethanol (combination)

CAS Number: URETHCOMB

Date Report Requested: 10/18/2014

Time Report Requested: 00:10:35

First Dose M/F: NA / NA

Lab: NCTR

B6C3F1/NCTR Mouse MALE	2.5%ETH/30PPMUR E	2.5%ETH/90PPMUR E	5.0%ETH/0PPM URE	5.0%ETH/10PPMUR E	5.0%ETH/30PPMUR E	5.0%ETH/90PPMUR E
Renal, Alveolar/Bronchiolar Carcinoma, Metastatic, Lung						1 (10%)
Renal, Lymphoma Malignant	2 (50%)	3 (50%)	1 (50%)	1 (33%)	3 (50%)	4 (40%)
Renal, Mesothelioma Malignant, Metastatic, Pancreas						
Squamous Cell Carcinoma, Metastatic, Skin	1 (25%)					
Thoracic, Lymphoma Malignant					1 (17%)	
Lymph Node, Mandibular	(45)	(47)	(48)	(47)	(48)	(47)
Carcinoma, Metastatic, Harderian Gland		1 (2%)				
Hemangiosarcoma		1 (2%)				
Histiocytic Sarcoma	1 (2%)	2 (4%)			1 (2%)	2 (4%)
Leukemia Granulocytic				1 (2%)		
Lymphoma Malignant	4 (9%)	3 (6%)	2 (4%)	5 (11%)	5 (10%)	8 (17%)
Neoplasm Nos						
Sarcoma, Metastatic, Skin			2 (4%)	1 (2%)		
Lymph Node, Mesenteric	(45)	(44)	(46)	(44)	(42)	(43)
Carcinoma, Metastatic, Harderian Gland		1 (2%)				
Hemangiosarcoma		3 (7%)				1 (2%)
Histiocytic Sarcoma	4 (9%)	4 (9%)			3 (7%)	4 (9%)
Leukemia Granulocytic				1 (2%)		
Lymphoma Malignant	6 (13%)	6 (14%)	6 (13%)	5 (11%)	7 (17%)	12 (28%)
Mesothelioma Malignant, Metastatic, Pancreas						
Mesothelioma Nos, Metastatic, Mesentery						
Neoplasm Nos, Metastatic, Thymus						
Sarcoma						
Sarcoma, Metastatic, Skin		1 (2%)				
Spleen	(46)	(46)	(48)	(46)	(46)	(45)
Hemangioma	1 (2%)					

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 00602-05

Test Type: CHRONIC

Route: DOSED WATER

Species/Strain: Mouse/B6C3F1/NCTR

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Test Compound: Urethane + ethanol (combination)

CAS Number: URETHCOMB

Date Report Requested: 10/18/2014

Time Report Requested: 00:10:35

First Dose M/F: NA / NA

Lab: NCTR

B6C3F1/NCTR Mouse MALE	2.5%ETH/30PPMUR E	2.5%ETH/90PPMUR E	5.0%ETH/0PPM URE	5.0%ETH/10PPMUR E	5.0%ETH/30PPMUR E	5.0%ETH/90PPMUR E
Hemangiosarcoma	1 (2%)	3 (7%)		1 (2%)		1 (2%)
Histiocytic Sarcoma	2 (4%)	3 (7%)	2 (4%)		3 (7%)	3 (7%)
Leukemia Granulocytic				1 (2%)		
Lymphoma Malignant	5 (11%)	5 (11%)	9 (19%)	9 (20%)	6 (13%)	10 (22%)
Mesothelioma Malignant, Metastatic, Pancreas						
Sarcoma, Metastatic, Skin					1 (2%)	
Thymus	(28)	(32)	(34)	(33)	(32)	(35)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung		2 (6%)				2 (6%)
Leukemia Granulocytic				1 (3%)		
Lymphoma Malignant	3 (11%)	3 (9%)		2 (6%)		10 (29%)
Neoplasm Nos						
Sarcoma						1 (3%)
Sarcoma, Metastatic, Skin		1 (3%)				
Sarcoma, Metastatic, Uncertain Primary Site						
Thymoma Benign					1 (3%)	1 (3%)
INTEGUMENTARY SYSTEM						
Mammary Gland	(2)	(1)	(1)	(1)	(2)	(1)
Carcinoma						
Lymphoma Malignant						
Skin	(46)	(47)	(48)	(47)	(48)	(45)
Basal Cell Adenoma						2 (4%)
Basal Cell Carcinoma						
Fibroma			2 (4%)	2 (4%)	1 (2%)	1 (2%)
Fibroma, Multiple	1 (2%)				1 (2%)	
Hemangioma						

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 00602-05

Test Type: CHRONIC

Route: DOSED WATER

Species/Strain: Mouse/B6C3F1/NCTR

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Test Compound: Urethane + ethanol (combination)

CAS Number: URETHCOMB

Date Report Requested: 10/18/2014

Time Report Requested: 00:10:35

First Dose M/F: NA / NA

Lab: NCTR

B6C3F1/NCTR Mouse MALE	2.5%ETH/30PPMUR E	2.5%ETH/90PPMUR E	5.0%ETH/0PPM URE	5.0%ETH/10PPMUR E	5.0%ETH/30PPMUR E	5.0%ETH/90PPMUR E
Hemangiosarcoma	4 (9%)	1 (2%)				1 (2%)
Histiocytic Sarcoma						
Histiocytic Sarcoma, Multiple						
Lipoma						1 (2%)
Lymphoma Malignant		1 (2%)			1 (2%)	2 (4%)
Neoplasm Nos						
Osteosarcoma					1 (2%)	
Prepuce, Fibroma						
Rhabdomyosarcoma, Metastatic, Skeletal Muscle						
Sarcoma	9 (20%)	7 (15%)	10 (21%)	8 (17%)	12 (25%)	11 (24%)
Sarcoma, Multiple	1 (2%)	1 (2%)	2 (4%)	2 (4%)	3 (6%)	1 (2%)
Sebaceous GI, Adenoma						1 (2%)
Squamous Cell Carcinoma	2 (4%)	4 (9%)				1 (2%)
Squamous Cell Papilloma	2 (4%)	3 (6%)		2 (4%)		6 (13%)
Squamous Cell Papilloma, Multiple						
Tail, Fibroma						
MUSCULOSKELETAL SYSTEM						
Bone	(47)	(48)	(48)	(48)	(47)	(47)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung		1 (2%)				
Cranium, Hemangiosarcoma						
Sternum, Carcinoma, Metastatic, Harderian Gland						1 (2%)
Sternum, Sarcoma, Metastatic, Uncertain Primary Site						
Vertebra, Alveolar/Bronchiolar Carcinoma, Metastatic, Lung		1 (2%)				
Skeletal Muscle	(47)	(48)	(48)	(48)	(48)	(47)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 00602-05

Test Type: CHRONIC

Route: DOSED WATER

Species/Strain: Mouse/B6C3F1/NCTR

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Test Compound: Urethane + ethanol (combination)

CAS Number: URETHCOMB

Date Report Requested: 10/18/2014

Time Report Requested: 00:10:35

First Dose M/F: NA / NA

Lab: NCTR

B6C3F1/NCTR Mouse MALE	2.5%ETH/30PPMUR E	2.5%ETH/90PPMUR E	5.0%ETH/0PPM URE	5.0%ETH/10PPMUR E	5.0%ETH/30PPMUR E	5.0%ETH/90PPMUR E
Alveolar/Bronchiolar Carcinoma, Metastatic		1 (2%)				
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung						
Diaphragm, Alveolar/Bronchiolar Carcinoma, Metastatic, Lung		1 (2%)				
Fibrosarcoma						
Histiocytic Sarcoma		1 (2%)				
Lymphoma Malignant	1 (2%)					1 (2%)
Neoplasm Nos, Metastatic, Thymus						
Rhabdomyosarcoma					1 (2%)	1 (2%)
Sarcoma				1 (2%)		
Sarcoma, Metastatic, Skin		1 (2%)		1 (2%)		
NERVOUS SYSTEM						
Brain, Cerebellum	(47)	(48)	(47)	(48)	(46)	(46)
Lymphoma Malignant		1 (2%)				
Brain, Cerebrum	(47)	(48)	(48)	(48)	(48)	(48)
Lymphoma Malignant		1 (2%)				2 (4%)
Meninges, Leukemia Granulocytic				1 (2%)		
Oligodendroglioma Malignant						
Peripheral Nerve	(47)	(48)	(47)	(48)	(48)	(47)
Schwannoma Malignant			1 (2%)			
Spinal Cord, Thoracic	(47)	(48)	(48)	(48)	(48)	(48)
Lymphoma Malignant		1 (2%)				
RESPIRATORY SYSTEM						
Larynx	(46)	(47)	(46)	(47)	(45)	(47)
Leukemia Granulocytic				1 (2%)		
Lymphoma Malignant		1 (2%)				3 (6%)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 00602-05

Test Type: CHRONIC

Route: DOSED WATER

Species/Strain: Mouse/B6C3F1/NCTR

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Test Compound: Urethane + ethanol (combination)

CAS Number: URETHCOMB

Date Report Requested: 10/18/2014

Time Report Requested: 00:10:35

First Dose M/F: NA / NA

Lab: NCTR

B6C3F1/NCTR Mouse MALE	2.5%ETH/30PPMUR E	2.5%ETH/90PPMUR E	5.0%ETH/0PPM URE	5.0%ETH/10PPMUR E	5.0%ETH/30PPMUR E	5.0%ETH/90PPMUR E
Lung	(47)	(48)	(48)	(48)	(48)	(48)
Alveolar/Bronchiolar Adenoma	11 (23%)	11 (23%)	5 (10%)	7 (15%)	6 (13%)	19 (40%)
Alveolar/Bronchiolar Adenoma, Multiple	8 (17%)	24 (50%)	1 (2%)	1 (2%)	3 (6%)	14 (29%)
Alveolar/Bronchiolar Carcinoma	7 (15%)	20 (42%)	5 (10%)	4 (8%)	5 (10%)	15 (31%)
Alveolar/Bronchiolar Carcinoma, Multiple	1 (2%)	4 (8%)				2 (4%)
Basal Cell Carcinoma, Metastatic, Skin						
Carcinoma, Metastatic, Harderian Gland		1 (2%)				1 (2%)
Hemangiosarcoma						1 (2%)
Hepatoblastoma, Metastatic, Liver						
Hepatocellular Carcinoma						
Hepatocellular Carcinoma, Metastatic, Liver	2 (4%)	3 (6%)		2 (4%)	1 (2%)	2 (4%)
Hepatocellular Carcinoma, Multiple, Metastatic, Liver						
Histiocytic Sarcoma	3 (6%)	4 (8%)			3 (6%)	3 (6%)
Leukemia Granulocytic				1 (2%)		
Lymphoma Malignant	2 (4%)	2 (4%)	2 (4%)	1 (2%)	2 (4%)	4 (8%)
Mesothelioma Malignant, Metastatic, Pancreas						
Mesothelioma Nos, Metastatic, Mesentery						
Neoplasm Nos						
Neoplasm Nos, Metastatic, Thymus						
Rhabdomyosarcoma, Metastatic, Skeletal Muscle						1 (2%)
Sarcoma, Metastatic, Skin		3 (6%)	1 (2%)	4 (8%)	2 (4%)	
Sarcoma, Metastatic, Thymus						1 (2%)
Schwannoma Malignant, Metastatic, Lung						
Schwannoma Malignant, Metastatic, Nose						
Nose	(47)	(48)	(48)	(48)	(48)	(46)
Leukemia Granulocytic				1 (2%)		

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 00602-05

Test Type: CHRONIC

Route: DOSED WATER

Species/Strain: Mouse/B6C3F1/NCTR

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Test Compound: Urethane + ethanol (combination)

CAS Number: URETHCOMB

Date Report Requested: 10/18/2014

Time Report Requested: 00:10:36

First Dose M/F: NA / NA

Lab: NCTR

B6C3F1/NCTR Mouse MALE	2.5%ETH/30PPMUR E	2.5%ETH/90PPMUR E	5.0%ETH/0PPM URE	5.0%ETH/10PPMUR E	5.0%ETH/30PPMUR E	5.0%ETH/90PPMUR E
Lymphoma Malignant	1 (2%)	1 (2%)				4 (9%)
Mucosa, Hemangioma						
Schwannoma Malignant						
Trachea	(45)	(48)	(47)	(48)	(48)	(48)
Leukemia Granulocytic				1 (2%)		
Lymphoma Malignant						2 (4%)
SPECIAL SENSES SYSTEM						
Ear	(1)	(0)	(0)	(0)	(0)	(1)
Eye	(47)	(46)	(48)	(48)	(48)	(46)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung						
Leukemia Granulocytic				1 (2%)		
Lymphoma Malignant		1 (2%)				
Schwannoma Malignant, Metastatic, Peripheral Nerve			1 (2%)			
Harderian Gland	(47)	(48)	(47)	(48)	(48)	(45)
Adenoma	17 (36%)	19 (40%)	5 (11%)	12 (25%)	12 (25%)	16 (36%)
Bilateral, Adenoma	4 (9%)	8 (17%)			3 (6%)	10 (22%)
Bilateral, Carcinoma		3 (6%)				3 (7%)
Carcinoma	1 (2%)	13 (27%)		2 (4%)	2 (4%)	7 (16%)
Leukemia Granulocytic				1 (2%)		
Lymphoma Malignant	1 (2%)	1 (2%)				1 (2%)
Lacrimal Gland	(45)	(46)	(47)	(47)	(48)	(47)
Leukemia Granulocytic				1 (2%)		
Lymphoma Malignant	1 (2%)	1 (2%)			1 (2%)	1 (2%)
Zymbal's Gland	(46)	(43)	(46)	(45)	(47)	(42)
Basosquamous Tumor Benign						
Carcinoma						1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 00602-05

Test Type: CHRONIC

Route: DOSED WATER

Species/Strain: Mouse/B6C3F1/NCTR

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Test Compound: Urethane + ethanol (combination)

CAS Number: URETHCOMB

Date Report Requested: 10/18/2014

Time Report Requested: 00:10:36

First Dose M/F: NA / NA

Lab: NCTR

B6C3F1/NCTR Mouse MALE	2.5%ETH/30PPMUR E	2.5%ETH/90PPMUR E	5.0%ETH/0PPM URE	5.0%ETH/10PPMUR E	5.0%ETH/30PPMUR E	5.0%ETH/90PPMUR E
Leukemia Granulocytic				1 (2%)		
Lymphoma Malignant		1 (2%)				1 (2%)
Sarcoma, Metastatic, Skin	1 (2%)					
URINARY SYSTEM						
Kidney	(47)	(47)	(48)	(47)	(48)	(48)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung						1 (2%)
Hemangiosarcoma		2 (4%)				3 (6%)
Histiocytic Sarcoma	2 (4%)	1 (2%)			1 (2%)	1 (2%)
Leukemia Granulocytic				1 (2%)		
Lymphoma Malignant	2 (4%)	3 (6%)			4 (8%)	7 (15%)
Mesothelioma Malignant, Metastatic, Pancreas						
Renal Tubule, Adenoma						
Renal Tubule, Adenoma, Multiple		1 (2%)				
Renal Tubule, Carcinoma						1 (2%)
Sarcoma, Metastatic, Skin		1 (2%)			2 (4%)	
Ureter	(1)	(0)	(0)	(0)	(0)	(0)
Urethra	(0)	(0)	(0)	(1)	(3)	(0)
Urinary Bladder	(45)	(46)	(48)	(47)	(48)	(45)
Carcinoma						1 (2%)
Hemangioma			2 (4%)	1 (2%)		
Histiocytic Sarcoma						
Leukemia Granulocytic				1 (2%)		
Lymphoma Malignant	1 (2%)	1 (2%)	1 (2%)			3 (7%)
SYSTEMIC LESIONS						
Multiple Organ	*(47)	*(48)	*(48)	*(48)	*(48)	*(48)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 00602-05
Test Type: CHRONIC
Route: DOSED WATER
Species/Strain: Mouse/B6C3F1/NCTR

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)
Test Compound: Urethane + ethanol (combination)
CAS Number: URETHCOMB

Date Report Requested: 10/18/2014
Time Report Requested: 00:10:36
First Dose M/F: NA / NA
Lab: NCTR

B6C3F1/NCTR Mouse MALE	2.5%ETH/30PPMUR E	2.5%ETH/90PPMUR E	5.0%ETH/0PPM URE	5.0%ETH/10PPMUR E	5.0%ETH/30PPMUR E	5.0%ETH/90PPMUR E
Histiocytic Sarcoma	5 (11%)	7 (15%)	2 (4%)		4 (8%)	5 (10%)
Leukemia Granulocytic				1 (2%)		
Lymphoma Malignant	10 (21%)	7 (15%)	12 (25%)	10 (21%)	8 (17%)	14 (29%)
Mesothelioma Malignant	1 (2%)					
Mesothelioma Nos						

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 00602-05
 Test Type: CHRONIC
 Route: DOSED WATER
 Species/Strain: Mouse/B6C3F1/NCTR

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)
 Test Compound: Urethane + ethanol (combination)
 CAS Number: URETHCOMB

Date Report Requested: 10/18/2014
 Time Report Requested: 00:10:36
 First Dose M/F: NA / NA
 Lab: NCTR

B6C3F1/NCTR Mouse MALE	0% ETH/ 0PPM URE	0% ETH/ 10PPMURE	0% ETH/ 30PPMURE	0% ETH/ 90PPMURE	2.5%ETH/0PPM URE	2.5%ETH/10PPMUR E
Tumor Summary for MALE						
Total Animals with Primary Neoplasms (b)	33	39	46	47	41	45
Total Primary Neoplasms	59	90	135	196	80	97
Total Animals with Benign Neoplasms	17	29	41	45	27	33
Total Benign Neoplasms	19	51	80	101	37	61
Total Animals with Malignant Neoplasms	27	30	37	43	31	32
Total Malignant Neoplasms	37	39	55	94	43	35
Total Animals with Metastatic Neoplasms	7	6	5	8	10	4
Total Metastatic Neoplasms	16	8	6	13	18	16
Total Animals with Malignant Neoplasms Uncertain Primary Site	1					
Total Animals with Neoplasms Uncertain - Benign or Malignant	2			1		1
Total Uncertain Neoplasms	2			1		1

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 00602-05
 Test Type: CHRONIC
 Route: DOSED WATER
 Species/Strain: Mouse/B6C3F1/NCTR

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)
 Test Compound: Urethane + ethanol (combination)
 CAS Number: URETHCOMB

Date Report Requested: 10/18/2014
 Time Report Requested: 00:10:36
 First Dose M/F: NA / NA
 Lab: NCTR

B6C3F1/NCTR Mouse MALE	2.5%ETH/30PPMUR E	2.5%ETH/90PPMUR E	5.0%ETH/0PPM URE	5.0%ETH/10PPMUR E	5.0%ETH/30PPMUR E	5.0%ETH/90PPMUR E
Tumor Summary for MALE						
Total Animals with Primary Neoplasms (b)	42	47	42	41	44	46
Total Primary Neoplasms	122	206	88	93	103	194
Total Animals with Benign Neoplasms	37	46	30	29	32	40
Total Benign Neoplasms	68	106	45	49	56	92
Total Animals with Malignant Neoplasms	33	45	31	30	37	45
Total Malignant Neoplasms	54	100	43	44	47	102
Total Animals with Metastatic Neoplasms	5	11	5	6	4	8
Total Metastatic Neoplasms	5	31	6	8	8	16
Total Animals with Malignant Neoplasms Uncertain Primary Site						
Total Animals with Neoplasms Uncertain - Benign or Malignant						
Total Uncertain Neoplasms						

END OF MALE DATA

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 00602-05
 Test Type: CHRONIC
 Route: DOSED WATER
 Species/Strain: Mouse/B6C3F1/NCTR

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)
 Test Compound: Urethane + ethanol (combination)
 CAS Number: URETHCOMB

Date Report Requested: 10/18/2014
 Time Report Requested: 00:10:36
 First Dose M/F: NA / NA
 Lab: NCTR

B6C3F1/NCTR Mouse FEMALE	0% ETH/ 0PPM URE	0% ETH/ 10PPMURE	0% ETH/ 30PPMURE	0% ETH/ 90PPMURE	2.5%ETH/0PPM URE	2.5%ETH/10PPMUR E
Disposition Summary						
Animals Initially In Study	48	48	48	48	48	47
Early Deaths						
Drowned					4	3
Moribund	1	3	4	14	1	2
Natural Death	5	7	13	22	2	7
Survivors						
Moribund			1	4		2
Natural Death	4	1	3	7	2	
Terminal Sacrifice	38	37	27	1	39	33
Animals Examined Microscopically	48	48	48	48	47	47
ALIMENTARY SYSTEM						
Esophagus	(48)	(47)	(47)	(47)	(47)	(47)
Lymphoma Malignant		1 (2%)				
Sarcoma, Metastatic, Kidney						
Gallbladder	(47)	(45)	(46)	(43)	(47)	(45)
Leiomyosarcoma, Metastatic, Uterus			1 (2%)			
Lymphoma Malignant	1 (2%)	1 (2%)	1 (2%)			
Sarcoma, Metastatic, Skin				1 (2%)		
Intestine Large	(0)	(0)	(0)	(0)	(0)	(0)
Intestine Large, Cecum	(48)	(45)	(46)	(45)	(47)	(45)
Lymphoma Malignant		1 (2%)				1 (2%)
Mast Cell Tumor Malignant						
Intestine Large, Colon	(48)	(44)	(46)	(46)	(47)	(45)
Lymphoma Malignant	1 (2%)					1 (2%)
Sarcoma, Metastatic, Skin				1 (2%)		

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 00602-05

Test Type: CHRONIC

Route: DOSED WATER

Species/Strain: Mouse/B6C3F1/NCTR

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Test Compound: Urethane + ethanol (combination)

CAS Number: URETHCOMB

Date Report Requested: 10/18/2014

Time Report Requested: 00:10:36

First Dose M/F: NA / NA

Lab: NCTR

B6C3F1/NCTR Mouse FEMALE	0% ETH/ 0PPM URE	0% ETH/ 10PPMURE	0% ETH/ 30PPMURE	0% ETH/ 90PPMURE	2.5%ETH/0PPM URE	2.5%ETH/10PPMURE
Sarcoma, Metastatic, Uncertain Primary Site				1 (2%)		
Sarcoma, Metastatic, Uterus			1 (2%)			
Intestine Large, Rectum	(48)	(45)	(45)	(46)	(47)	(44)
Histiocytic Sarcoma			1 (2%)	1 (2%)		
Leiomyosarcoma, Metastatic, Uterus			1 (2%)			
Lymphoma Malignant				2 (4%)	1 (2%)	
Sarcoma, Metastatic, Skin						
Sarcoma, Metastatic, Uterus			1 (2%)			
Squamous Cell Carcinoma						
Intestine Small	(0)	(1)	(0)	(0)	(0)	(0)
Polyp Adenomatous		1 (100%)				
Intestine Small, Duodenum	(48)	(43)	(44)	(44)	(47)	(45)
Adenoma						
Lymphoma Malignant					1 (2%)	
Intestine Small, Ileum	(48)	(44)	(46)	(44)	(47)	(45)
Histiocytic Sarcoma				1 (2%)		
Lymphoma Malignant	1 (2%)	1 (2%)	1 (2%)			1 (2%)
Intestine Small, Jejunum	(48)	(44)	(46)	(44)	(47)	(45)
Hemangioma						
Leiomyosarcoma, Metastatic, Uterus			1 (2%)			
Lymphoma Malignant	1 (2%)					
Sarcoma Stromal, Metastatic, Uterus						
Sarcoma, Metastatic, Skin						
Liver	(48)	(47)	(47)	(47)	(47)	(47)
Hemangiosarcoma			1 (2%)	7 (15%)	1 (2%)	2 (4%)
Hepatocellular Adenoma	3 (6%)	8 (17%)	10 (21%)	2 (4%)	4 (9%)	
Hepatocellular Adenoma, Multiple	2 (4%)	2 (4%)	9 (19%)	16 (34%)	2 (4%)	5 (11%)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 00602-05

Test Type: CHRONIC

Route: DOSED WATER

Species/Strain: Mouse/B6C3F1/NCTR

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Test Compound: Urethane + ethanol (combination)

CAS Number: URETHCOMB

Date Report Requested: 10/18/2014

Time Report Requested: 00:10:37

First Dose M/F: NA / NA

Lab: NCTR

B6C3F1/NCTR Mouse FEMALE	0% ETH/ 0PPM URE	0% ETH/ 10PPMURE	0% ETH/ 30PPMURE	0% ETH/ 90PPMURE	2.5%ETH/0PPM URE	2.5%ETH/10PPMUR E
Hepatocellular Carcinoma		1 (2%)	2 (4%)	1 (2%)	1 (2%)	
Hepatocellular Carcinoma, Multiple						
Histiocytic Sarcoma	1 (2%)	2 (4%)	3 (6%)	3 (6%)		2 (4%)
Ito Cell Tumor Malignant					1 (2%)	
Leiomyosarcoma, Metastatic, Uterus			1 (2%)			
Lymphoma Malignant	11 (23%)	3 (6%)	5 (11%)	10 (21%)	2 (4%)	7 (15%)
Mast Cell Tumor Malignant						
Osteosarcoma, Metastatic, Bone						1 (2%)
Sarcoma Stromal, Metastatic, Uterus						
Sarcoma, Metastatic, Skin				1 (2%)		
Mesentery	(3)	(4)	(7)	(6)	(2)	(5)
Hemangiosarcoma						
Lymphoma Malignant			1 (14%)			1 (20%)
Sarcoma						1 (20%)
Sarcoma, Metastatic, Kidney						
Sarcoma, Metastatic, Skin				2 (33%)		
Pancreas	(48)	(43)	(47)	(44)	(47)	(45)
Histiocytic Sarcoma				2 (5%)		
Leiomyosarcoma, Metastatic, Uterus			1 (2%)			
Lymphoma Malignant	7 (15%)	1 (2%)	3 (6%)	6 (14%)	1 (2%)	3 (7%)
Sarcoma						1 (2%)
Sarcoma Stromal, Metastatic, Uterus						
Sarcoma, Metastatic, Kidney						
Sarcoma, Metastatic, Skin				1 (2%)		
Sarcoma, Metastatic, Uncertain Primary Site				1 (2%)		
Teratoma Malignant, Metastatic, Ovary						
Salivary Glands	(48)	(48)	(48)	(47)	(47)	(47)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 00602-05
Test Type: CHRONIC
Route: DOSED WATER
Species/Strain: Mouse/B6C3F1/NCTR

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)
Test Compound: Urethane + ethanol (combination)
CAS Number: URETHCOMB

Date Report Requested: 10/18/2014
Time Report Requested: 00:10:37
First Dose M/F: NA / NA
Lab: NCTR

B6C3F1/NCTR Mouse FEMALE	0% ETH/ 0PPM URE	0% ETH/ 10PPMURE	0% ETH/ 30PPMURE	0% ETH/ 90PPMURE	2.5%ETH/0PPM URE	2.5%ETH/10PPMURE
Histiocytic Sarcoma						
Lymphoma Malignant	7 (15%)	3 (6%)	3 (6%)	8 (17%)	2 (4%)	4 (9%)
Mast Cell Tumor Malignant						
Stomach	(0)	(0)	(0)	(0)	(0)	(0)
Stomach, Forestomach	(48)	(46)	(46)	(46)	(47)	(46)
Lymphoma Malignant	1 (2%)	1 (2%)		1 (2%)		1 (2%)
Mast Cell Tumor Malignant			1 (2%)			
Sarcoma Stromal, Metastatic, Uterus						
Sarcoma, Metastatic, Kidney						
Squamous Cell Carcinoma		1 (2%)		1 (2%)		
Squamous Cell Papilloma	2 (4%)	3 (7%)	3 (7%)	3 (7%)		4 (9%)
Stomach, Glandular	(47)	(46)	(46)	(47)	(47)	(46)
Leiomyosarcoma, Metastatic, Uterus			1 (2%)			
Lymphoma Malignant	1 (2%)	1 (2%)		1 (2%)		2 (4%)
Mast Cell Tumor Malignant						
Sarcoma, Metastatic, Skin						
Tongue	(48)	(48)	(48)	(46)	(47)	(47)
Lymphoma Malignant						1 (2%)
CARDIOVASCULAR SYSTEM						
Blood Vessel	(47)	(47)	(48)	(46)	(47)	(47)
Lymphoma Malignant				2 (4%)		
Heart	(48)	(48)	(48)	(48)	(47)	(47)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung						
Hemangioma			1 (2%)			
Hemangiosarcoma			1 (2%)			
Histiocytic Sarcoma	1 (2%)		2 (4%)	3 (6%)		1 (2%)
Lymphoma Malignant	3 (6%)	2 (4%)		3 (6%)		1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 00602-05

Test Type: CHRONIC

Route: DOSED WATER

Species/Strain: Mouse/B6C3F1/NCTR

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Test Compound: Urethane + ethanol (combination)

CAS Number: URETHCOMB

Date Report Requested: 10/18/2014

Time Report Requested: 00:10:37

First Dose M/F: NA / NA

Lab: NCTR

B6C3F1/NCTR Mouse FEMALE	0% ETH/ 0PPM URE	0% ETH/ 10PPMURE	0% ETH/ 30PPMURE	0% ETH/ 90PPMURE	2.5%ETH/0PPM URE	2.5%ETH/10PPMUR E
Lymphoma Malignant	3 (6%)	2 (4%)		3 (6%)		1 (2%)
Squamous Cell Carcinoma, Metastatic, Intestine Large						
ENDOCRINE SYSTEM						
Adrenal Gland	(0)	(0)	(0)	(1)	(0)	(0)
Bilateral, Subcapsular, Adenoma						
Adrenal Gland, Cortex	(48)	(45)	(45)	(47)	(46)	(47)
Adenocarcinoma, Metastatic, Mammary Gland					1 (2%)	
Adenoma				1 (2%)	1 (2%)	
Bilateral, Adenoma				1 (2%)		
Hemangiosarcoma				1 (2%)		
Histiocytic Sarcoma			1 (2%)			
Lymphoma Malignant	1 (2%)	2 (4%)	2 (4%)	2 (4%)		3 (6%)
Osteosarcoma, Metastatic, Bone						
Sarcoma Stromal, Metastatic, Uterus						
Sarcoma, Metastatic, Kidney						
Sarcoma, Metastatic, Skin						
Sarcoma, Metastatic, Uncertain Primary Site				1 (2%)		
Subcapsular, Adenoma	1 (2%)		1 (2%)			1 (2%)
Subcapsular, Carcinoma						
Adrenal Gland, Medulla	(47)	(42)	(43)	(47)	(45)	(47)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung						
Lymphoma Malignant	1 (2%)	1 (2%)		1 (2%)		1 (2%)
Pheochromocytoma Benign					1 (2%)	1 (2%)
Pheochromocytoma Malignant						

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 00602-05

Test Type: CHRONIC

Route: DOSED WATER

Species/Strain: Mouse/B6C3F1/NCTR

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Test Compound: Urethane + ethanol (combination)

CAS Number: URETHCOMB

Date Report Requested: 10/18/2014

Time Report Requested: 00:10:37

First Dose M/F: NA / NA

Lab: NCTR

B6C3F1/NCTR Mouse FEMALE	0% ETH/ 0PPM URE	0% ETH/ 10PPMURE	0% ETH/ 30PPMURE	0% ETH/ 90PPMURE	2.5%ETH/0PPM URE	2.5%ETH/10PPMUR E
Islets, Pancreatic	(48)	(43)	(47)	(44)	(47)	(45)
Adenoma	1 (2%)				1 (2%)	1 (2%)
Histiocytic Sarcoma				1 (2%)		
Lymphoma Malignant	3 (6%)	1 (2%)	3 (6%)	2 (5%)		
Sarcoma, Metastatic, Skin						
Parathyroid Gland	(32)	(38)	(31)	(40)	(34)	(37)
Lymphoma Malignant		1 (3%)	1 (3%)			
Pituitary Gland	(42)	(42)	(40)	(39)	(44)	(41)
Histiocytic Sarcoma						
Lymphoma Malignant				2 (5%)		1 (2%)
Meningioma Malignant, Metastatic, Brain						
Pars Distalis, Adenoma	7 (17%)	4 (10%)	5 (13%)	1 (3%)	7 (16%)	2 (5%)
Pars Distalis, Carcinoma						
Thyroid Gland	(47)	(47)	(47)	(45)	(46)	(47)
Follicular Cel, Adenoma	1 (2%)		1 (2%)	2 (4%)	1 (2%)	
Follicular Cel, Carcinoma				1 (2%)		
Lymphoma Malignant	1 (2%)	1 (2%)				1 (2%)
GENERAL BODY SYSTEM						
Tissue NOS	(1)	(1)	(1)	(4)	(0)	(1)
Abdominal, Histiocytic Sarcoma						
Abdominal, Lymphoma Malignant	1 (100%)			1 (25%)		
Abdominal, Sarcoma			1 (100%)			1 (100%)
Histiocytic Sarcoma				1 (25%)		
Lymphoma Malignant		1 (100%)		1 (25%)		
Sarcoma				1 (25%)		
Thoracic, Alveolar/Bronchiolar Carcinoma, Metastatic, Lung						

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 00602-05

Test Type: CHRONIC

Route: DOSED WATER

Species/Strain: Mouse/B6C3F1/NCTR

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Test Compound: Urethane + ethanol (combination)

CAS Number: URETHCOMB

Date Report Requested: 10/18/2014

Time Report Requested: 00:10:37

First Dose M/F: NA / NA

Lab: NCTR

B6C3F1/NCTR Mouse FEMALE	0% ETH/ 0PPM URE	0% ETH/ 10PPMURE	0% ETH/ 30PPMURE	0% ETH/ 90PPMURE	2.5%ETH/0PPM URE	2.5%ETH/10PPMUR E
GENITAL SYSTEM						
Clitoral Gland	(43)	(41)	(43)	(37)	(40)	(40)
Lymphoma Malignant					1 (3%)	1 (3%)
Ovary	(48)	(46)	(46)	(39)	(47)	(46)
Adenoma, Tubular			2 (4%)	1 (3%)	1 (2%)	
Cystadenoma	2 (4%)		1 (2%)	1 (3%)	1 (2%)	2 (4%)
Granulosa Cell Tumor Benign			2 (4%)	3 (8%)		
Granulosa Cell Tumor Malignant				3 (8%)		
Hemangioma	1 (2%)					
Hemangiosarcoma						
Histiocytic Sarcoma	1 (2%)	1 (2%)	3 (7%)			1 (2%)
Luteoma		1 (2%)				
Lymphoma Malignant	4 (8%)	3 (7%)	3 (7%)	8 (21%)	1 (2%)	4 (9%)
Sarcoma Stromal, Metastatic, Uterus						
Sarcoma, Metastatic, Skin						
Teratoma Malignant						
Thecoma Benign						
Uterus	(48)	(47)	(48)	(46)	(47)	(47)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung						
Endometrium, Adenoma		1 (2%)		1 (2%)		
Hemangioma		1 (2%)	2 (4%)			
Hemangiosarcoma				2 (4%)		
Histiocytic Sarcoma	1 (2%)	1 (2%)	3 (6%)	2 (4%)		1 (2%)
Leiomyoma					1 (2%)	
Leiomyosarcoma			1 (2%)			
Lymphoma Malignant	2 (4%)	2 (4%)		3 (7%)	1 (2%)	1 (2%)
Polyp Stromal			1 (2%)	1 (2%)		

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 00602-05

Test Type: CHRONIC

Route: DOSED WATER

Species/Strain: Mouse/B6C3F1/NCTR

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Test Compound: Urethane + ethanol (combination)

CAS Number: URETHCOMB

Date Report Requested: 10/18/2014

Time Report Requested: 00:10:37

First Dose M/F: NA / NA

Lab: NCTR

B6C3F1/NCTR Mouse FEMALE	0% ETH/ 0PPM URE	0% ETH/ 10PPMURE	0% ETH/ 30PPMURE	0% ETH/ 90PPMURE	2.5%ETH/0PPM URE	2.5%ETH/10PPMURE
Sarcoma			1 (2%)	1 (2%)		
Sarcoma Stromal	1 (2%)		1 (2%)			
Sarcoma, Metastatic, Skin						
Vagina	(48)	(47)	(46)	(43)	(47)	(47)
Basosquamous Tumor Benign		1 (2%)				
Hemangioma						
Histiocytic Sarcoma						1 (2%)
Leiomyosarcoma, Metastatic, Uterus			1 (2%)			
Lymphoma Malignant	3 (6%)	2 (4%)		4 (9%)	1 (2%)	1 (2%)
Sarcoma Stromal, Metastatic, Uterus						
Sarcoma, Metastatic, Skin	1 (2%)					
Sarcoma, Metastatic, Uterus			1 (2%)			
Squamous Cell Carcinoma				1 (2%)		
Squamous Cell Papilloma				1 (2%)		
HEMATOPOIETIC SYSTEM						
Bone Marrow	(48)	(47)	(46)	(47)	(47)	(46)
Hemangiosarcoma						
Histiocytic Sarcoma			1 (2%)			1 (2%)
Lymphoma Malignant			1 (2%)	1 (2%)		
Lymph Node	(6)	(4)	(9)	(12)	(1)	(8)
Axillary, Lymphoma Malignant	2 (33%)	1 (25%)				1 (13%)
Axillary, Sarcoma, Metastatic, Skin						
Hemal, Lymphoma Malignant						
Iliac, Histiocytic Sarcoma			1 (11%)			
Iliac, Lymphoma Malignant						
Inguinal, Histiocytic Sarcoma			1 (11%)			
Inguinal, Lymphoma Malignant		1 (25%)				

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 00602-05

Test Type: CHRONIC

Route: DOSED WATER

Species/Strain: Mouse/B6C3F1/NCTR

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Test Compound: Urethane + ethanol (combination)

CAS Number: URETHCOMB

Date Report Requested: 10/18/2014

Time Report Requested: 00:10:38

First Dose M/F: NA / NA

Lab: NCTR

B6C3F1/NCTR Mouse FEMALE	0% ETH/ 0PPM URE	0% ETH/ 10PPMURE	0% ETH/ 30PPMURE	0% ETH/ 90PPMURE	2.5%ETH/0PPM URE	2.5%ETH/10PPMURE
Inguinal, Sarcoma, Metastatic, Skin						
Lumbar, Alveolar/Bronchiolar Carcinoma, Metastatic, Lung						
Lumbar, Histiocytic Sarcoma			1 (11%)	1 (8%)		1 (13%)
Lumbar, Lymphoma Malignant	3 (50%)	3 (75%)	3 (33%)	5 (42%)		2 (25%)
Lumbar, Sarcoma Stromal, Metastatic, Uterus						
Lumbar, Sarcoma, Metastatic, Skin						
Pancreatic, Histiocytic Sarcoma						
Pancreatic, Lymphoma Malignant	1 (17%)	1 (25%)				
Renal, Histiocytic Sarcoma				1 (8%)		
Renal, Leiomyosarcoma, Metastatic, Uterus			1 (11%)			
Renal, Lymphangioma				1 (8%)		
Renal, Lymphoma Malignant	4 (67%)	1 (25%)	2 (22%)	3 (25%)		2 (25%)
Renal, Sarcoma Stromal, Metastatic, Uterus						
Renal, Sarcoma, Metastatic, Skin						
Thoracic, Lymphoma Malignant	1 (17%)	2 (50%)	1 (11%)	2 (17%)		3 (38%)
Thoracic, Sarcoma Stromal, Metastatic, Uterus						
Lymph Node, Mandibular	(45)	(47)	(45)	(42)	(47)	(44)
Adenocarcinoma, Metastatic, Uncertain Primary Site				1 (2%)		
Histiocytic Sarcoma		1 (2%)	1 (2%)	1 (2%)		2 (5%)
Lymphoma Malignant	9 (20%)	4 (9%)	5 (11%)	11 (26%)	4 (9%)	4 (9%)
Mast Cell Tumor Malignant						
Lymph Node, Mesenteric	(47)	(45)	(42)	(39)	(43)	(42)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung						
Histiocytic Sarcoma		2 (4%)	2 (5%)	3 (8%)		1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 00602-05

Test Type: CHRONIC

Route: DOSED WATER

Species/Strain: Mouse/B6C3F1/NCTR

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Test Compound: Urethane + ethanol (combination)

CAS Number: URETHCOMB

Date Report Requested: 10/18/2014

Time Report Requested: 00:10:38

First Dose M/F: NA / NA

Lab: NCTR

B6C3F1/NCTR Mouse FEMALE	0% ETH/ 0PPM URE	0% ETH/ 10PPMURE	0% ETH/ 30PPMURE	0% ETH/ 90PPMURE	2.5%ETH/0PPM URE	2.5%ETH/10PPMURE
Leiomyosarcoma, Metastatic, Uterus			1 (2%)			
Lymphoma Malignant	13 (28%)	6 (13%)	7 (17%)	11 (28%)	5 (12%)	6 (14%)
Mast Cell Tumor Malignant						
Sarcoma		1 (2%)				
Sarcoma Stromal, Metastatic, Uterus						
Sarcoma, Metastatic, Kidney						
Sarcoma, Metastatic, Skin						
Sarcoma, Metastatic, Uncertain Primary Site				1 (3%)		
Spleen	(48)	(45)	(47)	(46)	(47)	(46)
Hemangioma						1 (2%)
Hemangiosarcoma			1 (2%)	4 (9%)		
Histiocytic Sarcoma			2 (4%)	2 (4%)		2 (4%)
Leiomyosarcoma, Metastatic, Uterus			1 (2%)			
Lymphoma Malignant	15 (31%)	4 (9%)	7 (15%)	13 (28%)	6 (13%)	8 (17%)
Mast Cell Tumor Malignant						
Sarcoma Stromal, Metastatic, Uterus						
Sarcoma, Metastatic, Lymph Node		1 (2%)				
Sarcoma, Metastatic, Skin				1 (2%)		
Thymus	(40)	(37)	(32)	(38)	(41)	(40)
Adenocarcinoma, Metastatic, Mammary Gland						
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung				4 (11%)		
Histiocytic Sarcoma		1 (3%)	3 (9%)	1 (3%)		
Leiomyosarcoma, Metastatic, Uterus			1 (3%)			
Lymphoma Malignant	10 (25%)	3 (8%)	7 (22%)	10 (26%)	3 (7%)	5 (13%)
Sarcoma, Metastatic, Kidney						
Sarcoma, Metastatic, Skin				1 (3%)		

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 00602-05

Test Type: CHRONIC

Route: DOSED WATER

Species/Strain: Mouse/B6C3F1/NCTR

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Test Compound: Urethane + ethanol (combination)

CAS Number: URETHCOMB

Date Report Requested: 10/18/2014

Time Report Requested: 00:10:38

First Dose M/F: NA / NA

Lab: NCTR

B6C3F1/NCTR Mouse FEMALE	0% ETH/ 0PPM URE	0% ETH/ 10PPMURE	0% ETH/ 30PPMURE	0% ETH/ 90PPMURE	2.5%ETH/0PPM URE	2.5%ETH/10PPMUR E
Sarcoma, Metastatic, Uncertain Primary Site				1 (3%)		
INTEGUMENTARY SYSTEM						
Mammary Gland	(47)	(46)	(46)	(48)	(47)	(45)
Adenoacanthoma		1 (2%)	1 (2%)	11 (23%)		
Adenocarcinoma	4 (9%)	3 (7%)	3 (7%)	11 (23%)	4 (9%)	3 (7%)
Adenoma			2 (4%)	1 (2%)		
Basosquamous Tumor Malignant			1 (2%)			
Fibroadenoma				1 (2%)		
Lymphatic, Mast Cell Tumor Malignant						
Lymphoma Malignant	1 (2%)			1 (2%)	1 (2%)	1 (2%)
Sarcoma, Metastatic, Skin				1 (2%)		
Skin	(48)	(48)	(46)	(48)	(47)	(47)
Basal Cell Carcinoma			1 (2%)	1 (2%)		
Basosquamous Tumor Malignant			1 (2%)			
Fibroma						
Fibrous Histiocytoma		1 (2%)				
Hemangioma					1 (2%)	
Hemangiosarcoma				2 (4%)		
Lymphoma Malignant		1 (2%)		3 (6%)		
Osteosarcoma						
Papilloma		1 (2%)				
Sarcoma	4 (8%)	3 (6%)		6 (13%)	2 (4%)	1 (2%)
Squamous Cell Carcinoma, Metastatic, Intestine Large						
MUSCULOSKELETAL SYSTEM						
Bone	(48)	(48)	(48)	(48)	(46)	(47)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 00602-05
Test Type: CHRONIC
Route: DOSED WATER
Species/Strain: Mouse/B6C3F1/NCTR

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)
Test Compound: Urethane + ethanol (combination)
CAS Number: URETHCOMB

Date Report Requested: 10/18/2014
Time Report Requested: 00:10:38
First Dose M/F: NA / NA
Lab: NCTR

B6C3F1/NCTR Mouse FEMALE	0% ETH/ 0PPM URE	0% ETH/ 10PPMURE	0% ETH/ 30PPMURE	0% ETH/ 90PPMURE	2.5%ETH/0PPM URE	2.5%ETH/10PPMUR E
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung						
Femur, Hemangioma				1 (2%)		
Femur, Hemangiosarcoma						
Femur, Lymphoma Malignant				1 (2%)		
Femur, Sarcoma, Metastatic, Skin						
Humerus, Osteosarcoma						
Rib, Osteosarcoma						
Rib, Right, Osteosarcoma				1 (2%)		
Right, Osteosarcoma						1 (2%)
Sternum, Lymphoma Malignant	1 (2%)					
Sternum, Sarcoma				1 (2%)		
Sternum, Sarcoma, Metastatic, Skin				1 (2%)		
Vertebra, Osteosarcoma						
Skeletal Muscle	(48)	(48)	(48)	(48)	(47)	(47)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung				1 (2%)		
Diaphragm, Adenocarcinoma, Metastatic, Mammary Gland						
Diaphragm, Alveolar/Bronchiolar Carcinoma, Metastatic, Lung						
Diaphragm, Sarcoma, Metastatic, Skin				1 (2%)		
Diaphragm, Teratoma Malignant, Metastatic, Ovary						
Hemangiosarcoma			1 (2%)			
Lymphoma Malignant	1 (2%)	2 (4%)		3 (6%)	2 (4%)	2 (4%)
Mast Cell Tumor Malignant						
Rhabdomyosarcoma		1 (2%)				
Sarcoma						

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 00602-05
Test Type: CHRONIC
Route: DOSED WATER
Species/Strain: Mouse/B6C3F1/NCTR

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)
Test Compound: Urethane + ethanol (combination)
CAS Number: URETHCOMB

Date Report Requested: 10/18/2014
Time Report Requested: 00:10:38
First Dose M/F: NA / NA
Lab: NCTR

B6C3F1/NCTR Mouse FEMALE	0% ETH/ 0PPM URE	0% ETH/ 10PPMURE	0% ETH/ 30PPMURE	0% ETH/ 90PPMURE	2.5%ETH/0PPM URE	2.5%ETH/10PPMURE
Sarcoma, Metastatic, Skin	1 (2%)					
Sarcoma, Metastatic, Uncertain Primary Site				1 (2%)		
NERVOUS SYSTEM						
Brain	(0)	(0)	(0)	(0)	(0)	(0)
Brain, Brain Stem	(0)	(0)	(0)	(0)	(0)	(0)
Brain, Cerebellum	(48)	(48)	(48)	(48)	(47)	(46)
Lymphoma Malignant						
Brain, Cerebrum	(48)	(48)	(48)	(48)	(47)	(47)
Carcinoma, Deep Invasion						
Lymphoma Malignant				1 (2%)		
Meningioma Malignant						
Peripheral Nerve	(48)	(47)	(48)	(48)	(47)	(46)
Lymphoma Malignant					1 (2%)	
Spinal Cord	(0)	(0)	(0)	(0)	(0)	(0)
Spinal Cord, Thoracic	(48)	(48)	(48)	(48)	(47)	(47)
Lymphoma Malignant						
RESPIRATORY SYSTEM						
Larynx	(48)	(46)	(46)	(45)	(47)	(46)
Lymphoma Malignant		1 (2%)				
Lung	(48)	(48)	(48)	(47)	(47)	(47)
Adenoacanthoma, Metastatic, Mammary Gland		1 (2%)		5 (11%)		
Adenocarcinoma, Metastatic, Mammary Gland						
Adenocarcinoma, Multiple, Metastatic, Mammary Gland					1 (2%)	
Alveolar/Bronchiolar Adenoma	4 (8%)	6 (13%)	13 (27%)	12 (26%)	5 (11%)	7 (15%)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 00602-05

Test Type: CHRONIC

Route: DOSED WATER

Species/Strain: Mouse/B6C3F1/NCTR

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Test Compound: Urethane + ethanol (combination)

CAS Number: URETHCOMB

Date Report Requested: 10/18/2014

Time Report Requested: 00:10:38

First Dose M/F: NA / NA

Lab: NCTR

B6C3F1/NCTR Mouse FEMALE	0% ETH/ 0PPM URE	0% ETH/ 10PPMURE	0% ETH/ 30PPMURE	0% ETH/ 90PPMURE	2.5%ETH/0PPM URE	2.5%ETH/10PPMURE
Alveolar/Bronchiolar Adenoma, Multiple			4 (8%)	17 (36%)		3 (6%)
Alveolar/Bronchiolar Carcinoma	2 (4%)	4 (8%)	10 (21%)	6 (13%)		2 (4%)
Alveolar/Bronchiolar Carcinoma, Multiple			3 (6%)	13 (28%)		
Basal Cell Carcinoma, Metastatic, Skin			1 (2%)			
Basosquamous Tumor Malignant, Metastatic, Mammary Gland			1 (2%)			
Basosquamous Tumor Malignant, Metastatic, Zymbal'S Gland				1 (2%)		
Carcinoma, Metastatic, Harderian Gland				1 (2%)		
Carcinoma, Metastatic, Mammary Gland				1 (2%)		
Carcinoma, Metastatic, Zymbal'S Gland						1 (2%)
Granulosa Cell Tumor Malignant, Metastatic, Ovary				1 (2%)		
Hemangiosarcoma				1 (2%)		
Hepatocellular Carcinoma, Metastatic, Liver				1 (2%)		
Histiocytic Sarcoma		1 (2%)	3 (6%)	1 (2%)		2 (4%)
Leukemia						
Lymphoma Malignant	8 (17%)	3 (6%)	4 (8%)	8 (17%)	1 (2%)	6 (13%)
Osteosarcoma, Metastatic, Bone						1 (2%)
Osteosarcoma, Metastatic, Skin						
Sarcoma Stromal, Metastatic, Uterus						
Sarcoma, Metastatic, Skin						
Sarcoma, Metastatic, Uncertain Primary Site						
Squamous Cell Carcinoma, Metastatic, Intestine Large						
Nose	(48)	(48)	(48)	(46)	(47)	(47)
Carcinoma, Metastatic, Harderian Gland						
Lymphoma Malignant						

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 00602-05

Test Type: CHRONIC

Route: DOSED WATER

Species/Strain: Mouse/B6C3F1/NCTR

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Test Compound: Urethane + ethanol (combination)

CAS Number: URETHCOMB

Date Report Requested: 10/18/2014

Time Report Requested: 00:10:39

First Dose M/F: NA / NA

Lab: NCTR

B6C3F1/NCTR Mouse FEMALE	0% ETH/ 0PPM URE	0% ETH/ 10PPMURE	0% ETH/ 30PPMURE	0% ETH/ 90PPMURE	2.5%ETH/0PPM URE	2.5%ETH/10PPMUR E
Trachea	(48)	(47)	(47)	(46)	(47)	(47)
SPECIAL SENSES SYSTEM						
Ear	(0)	(0)	(0)	(0)	(0)	(0)
Squamous Cell Papilloma						
Eye	(48)	(47)	(46)	(48)	(47)	(45)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung						
Lymphoma Malignant						
Harderian Gland	(48)	(48)	(48)	(48)	(47)	(47)
Adenoma	3 (6%)	10 (21%)	8 (17%)	20 (42%)	2 (4%)	3 (6%)
Bilateral, Adenoma				1 (2%)		
Bilateral, Carcinoma				4 (8%)		
Carcinoma		1 (2%)	11 (23%)	7 (15%)	1 (2%)	3 (6%)
Histiocytic Sarcoma						
Lymphoma Malignant		2 (4%)		1 (2%)	1 (2%)	
Lacrimal Gland	(45)	(47)	(43)	(40)	(45)	(45)
Histiocytic Sarcoma						
Lymphoma Malignant	4 (9%)	2 (4%)	3 (7%)	1 (3%)	2 (4%)	3 (7%)
Mast Cell Tumor Malignant						
Zymbal's Gland	(46)	(43)	(46)	(46)	(46)	(43)
Basosquamous Tumor Malignant				1 (2%)		
Carcinoma						1 (2%)
Lymphoma Malignant		1 (2%)		1 (2%)		
URINARY SYSTEM						
Kidney	(48)	(48)	(48)	(48)	(47)	(47)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung						

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 00602-05
Test Type: CHRONIC
Route: DOSED WATER
Species/Strain: Mouse/B6C3F1/NCTR

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)
Test Compound: Urethane + ethanol (combination)
CAS Number: URETHCOMB

Date Report Requested: 10/18/2014
Time Report Requested: 00:10:39
First Dose M/F: NA / NA
Lab: NCTR

B6C3F1/NCTR Mouse FEMALE	0% ETH/ 0PPM URE	0% ETH/ 10PPMURE	0% ETH/ 30PPMURE	0% ETH/ 90PPMURE	2.5%ETH/0PPM URE	2.5%ETH/10PPMURE
Hemangiosarcoma						
Histiocytic Sarcoma			2 (4%)		1 (2%)	1 (2%)
Lymphoma Malignant	6 (13%)	2 (4%)	2 (4%)	8 (17%)	1 (2%)	6 (13%)
Mast Cell Tumor Malignant						
Osteosarcoma, Metastatic, Bone						
Osteosarcoma, Metastatic, Skin						
Perirenal Tiss, Hemangiosarcoma						
Sarcoma				1 (2%)		1 (2%)
Sarcoma, Metastatic, Skin				2 (4%)		
Urinary Bladder	(48)	(46)	(45)	(41)	(45)	(43)
Histiocytic Sarcoma						
Leiomyosarcoma, Metastatic, Uterus			1 (2%)			
Lymphoma Malignant	2 (4%)	1 (2%)	1 (2%)	5 (12%)	1 (2%)	1 (2%)
SYSTEMIC LESIONS						
Multiple Organ	*(48)	*(48)	*(48)	*(48)	*(47)	*(47)
Histiocytic Sarcoma	1 (2%)	2 (4%)	3 (6%)	3 (6%)		2 (4%)
Leukemia						
Lymphoma Malignant	16 (33%)	6 (13%)	8 (17%)	15 (31%)	9 (19%)	10 (21%)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 00602-05

Test Type: CHRONIC

Route: DOSED WATER

Species/Strain: Mouse/B6C3F1/NCTR

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Test Compound: Urethane + ethanol (combination)

CAS Number: URETHCOMB

Date Report Requested: 10/18/2014

Time Report Requested: 00:10:39

First Dose M/F: NA / NA

Lab: NCTR

B6C3F1/NCTR Mouse FEMALE	2.5%ETH/30PPMUR E	2.5%ETH/90PPMUR E	5.0%ETH/0PPM URE	5.0%ETH/10PPMUR E	5.0%ETH/30PPMUR E	5.0%ETH/90PPMUR E
Disposition Summary						
Animals Initially In Study	48	48	48	48	48	48
Early Deaths						
Drowned			4	2		
Moribund	11	7	2	1	3	8
Natural Death	16	25	5	8	13	26
Survivors						
Moribund		2	4	3	1	3
Natural Death	2	6	2	2	4	7
Terminal Sacrifice	19	8	31	32	27	4
Animals Examined Microscopically	48	48	48	48	48	48
ALIMENTARY SYSTEM						
Esophagus	(47)	(47)	(47)	(48)	(47)	(46)
Lymphoma Malignant					1 (2%)	
Sarcoma, Metastatic, Kidney		1 (2%)				
Gallbladder	(46)	(43)	(47)	(44)	(47)	(45)
Leiomyosarcoma, Metastatic, Uterus						
Lymphoma Malignant	1 (2%)		1 (2%)		2 (4%)	1 (2%)
Sarcoma, Metastatic, Skin						
Intestine Large	(0)	(0)	(1)	(0)	(6)	(0)
Intestine Large, Cecum	(47)	(41)	(47)	(44)	(42)	(42)
Lymphoma Malignant	1 (2%)	1 (2%)			1 (2%)	
Mast Cell Tumor Malignant				1 (2%)		
Intestine Large, Colon	(47)	(42)	(47)	(45)	(41)	(42)
Lymphoma Malignant		1 (2%)				
Sarcoma, Metastatic, Skin						1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 00602-05

Test Type: CHRONIC

Route: DOSED WATER

Species/Strain: Mouse/B6C3F1/NCTR

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Test Compound: Urethane + ethanol (combination)

CAS Number: URETHCOMB

Date Report Requested: 10/18/2014

Time Report Requested: 00:10:39

First Dose M/F: NA / NA

Lab: NCTR

B6C3F1/NCTR Mouse FEMALE	2.5%ETH/30PPMUR E	2.5%ETH/90PPMUR E	5.0%ETH/0PPM URE	5.0%ETH/10PPMUR E	5.0%ETH/30PPMUR E	5.0%ETH/90PPMUR E
Sarcoma, Metastatic, Uncertain Primary Site						
Sarcoma, Metastatic, Uterus						
Intestine Large, Rectum	(47)	(46)	(48)	(47)	(39)	(44)
Histiocytic Sarcoma						
Leiomyosarcoma, Metastatic, Uterus						
Lymphoma Malignant		1 (2%)			1 (3%)	
Sarcoma, Metastatic, Skin				1 (2%)		
Sarcoma, Metastatic, Uterus		1 (2%)				
Squamous Cell Carcinoma		1 (2%)				
Intestine Small	(0)	(0)	(0)	(0)	(6)	(0)
Polyp Adenomatous						
Intestine Small, Duodenum	(47)	(39)	(47)	(44)	(38)	(40)
Adenoma			1 (2%)			
Lymphoma Malignant				1 (2%)	1 (3%)	
Intestine Small, Ileum	(47)	(40)	(47)	(44)	(41)	(40)
Histiocytic Sarcoma						
Lymphoma Malignant	1 (2%)		1 (2%)		1 (2%)	1 (3%)
Intestine Small, Jejunum	(47)	(39)	(47)	(44)	(40)	(40)
Hemangioma						1 (3%)
Leiomyosarcoma, Metastatic, Uterus						
Lymphoma Malignant	1 (2%)					
Sarcoma Stromal, Metastatic, Uterus	1 (2%)					
Sarcoma, Metastatic, Skin	1 (2%)					
Liver	(47)	(46)	(48)	(47)	(48)	(48)
Hemangiosarcoma		7 (15%)				6 (13%)
Hepatocellular Adenoma	6 (13%)	9 (20%)	3 (6%)	4 (9%)	5 (10%)	2 (4%)
Hepatocellular Adenoma, Multiple	9 (19%)	14 (30%)		2 (4%)	11 (23%)	14 (29%)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 00602-05

Test Type: CHRONIC

Route: DOSED WATER

Species/Strain: Mouse/B6C3F1/NCTR

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Test Compound: Urethane + ethanol (combination)

CAS Number: URETHCOMB

Date Report Requested: 10/18/2014

Time Report Requested: 00:10:39

First Dose M/F: NA / NA

Lab: NCTR

B6C3F1/NCTR Mouse FEMALE	2.5%ETH/30PPMUR E	2.5%ETH/90PPMUR E	5.0%ETH/0PPM URE	5.0%ETH/10PPMUR E	5.0%ETH/30PPMUR E	5.0%ETH/90PPMUR E
Hepatocellular Carcinoma	3 (6%)	1 (2%)		1 (2%)		
Hepatocellular Carcinoma, Multiple						1 (2%)
Histiocytic Sarcoma	2 (4%)	1 (2%)	4 (8%)		3 (6%)	2 (4%)
Ito Cell Tumor Malignant						
Leiomyosarcoma, Metastatic, Uterus						
Lymphoma Malignant	5 (11%)	3 (7%)	4 (8%)	3 (6%)	9 (19%)	6 (13%)
Mast Cell Tumor Malignant				1 (2%)		
Osteosarcoma, Metastatic, Bone	1 (2%)					
Sarcoma Stromal, Metastatic, Uterus	1 (2%)				1 (2%)	1 (2%)
Sarcoma, Metastatic, Skin	1 (2%)			1 (2%)		1 (2%)
Mesentery	(6)	(6)	(3)	(3)	(5)	(4)
Hemangiosarcoma		1 (17%)				2 (50%)
Lymphoma Malignant	1 (17%)		1 (33%)			
Sarcoma						
Sarcoma, Metastatic, Kidney		1 (17%)				
Sarcoma, Metastatic, Skin						
Pancreas	(46)	(44)	(47)	(45)	(48)	(44)
Histiocytic Sarcoma		1 (2%)	3 (6%)		1 (2%)	1 (2%)
Leiomyosarcoma, Metastatic, Uterus						
Lymphoma Malignant	3 (7%)	1 (2%)			5 (10%)	1 (2%)
Sarcoma						
Sarcoma Stromal, Metastatic, Uterus	1 (2%)				1 (2%)	1 (2%)
Sarcoma, Metastatic, Kidney		1 (2%)				
Sarcoma, Metastatic, Skin	1 (2%)			1 (2%)		1 (2%)
Sarcoma, Metastatic, Uncertain Primary Site						
Teratoma Malignant, Metastatic, Ovary				1 (2%)		
Salivary Glands	(46)	(48)	(48)	(47)	(48)	(47)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 00602-05

Test Type: CHRONIC

Route: DOSED WATER

Species/Strain: Mouse/B6C3F1/NCTR

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Test Compound: Urethane + ethanol (combination)

CAS Number: URETHCOMB

Date Report Requested: 10/18/2014

Time Report Requested: 00:10:39

First Dose M/F: NA / NA

Lab: NCTR

B6C3F1/NCTR Mouse FEMALE	2.5%ETH/30PPMUR E	2.5%ETH/90PPMUR E	5.0%ETH/0PPM URE	5.0%ETH/10PPMUR E	5.0%ETH/30PPMUR E	5.0%ETH/90PPMUR E
Histiocytic Sarcoma			1 (2%)			
Lymphoma Malignant	3 (7%)	1 (2%)	1 (2%)		5 (10%)	1 (2%)
Mast Cell Tumor Malignant				1 (2%)		
Stomach	(0)	(0)	(0)	(0)	(7)	(0)
Stomach, Forestomach	(47)	(46)	(48)	(47)	(41)	(45)
Lymphoma Malignant						1 (2%)
Mast Cell Tumor Malignant						1 (2%)
Sarcoma Stromal, Metastatic, Uterus	1 (2%)					
Sarcoma, Metastatic, Kidney		1 (2%)				
Squamous Cell Carcinoma		1 (2%)				
Squamous Cell Papilloma			2 (4%)	3 (6%)	2 (5%)	
Stomach, Glandular	(47)	(45)	(48)	(46)	(40)	(45)
Leiomyosarcoma, Metastatic, Uterus						
Lymphoma Malignant						1 (2%)
Mast Cell Tumor Malignant				1 (2%)		
Sarcoma, Metastatic, Skin						1 (2%)
Tongue	(48)	(48)	(47)	(48)	(48)	(46)
Lymphoma Malignant						
CARDIOVASCULAR SYSTEM						
Blood Vessel	(48)	(48)	(47)	(48)	(46)	(45)
Lymphoma Malignant		2 (4%)			1 (2%)	1 (2%)
Heart	(48)	(48)	(47)	(48)	(48)	(47)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung		1 (2%)			1 (2%)	1 (2%)
Hemangioma					2 (4%)	
Hemangiosarcoma		3 (6%)				6 (13%)
Histiocytic Sarcoma						
Lymphoma Malignant	1 (2%)	3 (6%)		1 (2%)	2 (4%)	2 (4%)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 00602-05

Test Type: CHRONIC

Route: DOSED WATER

Species/Strain: Mouse/B6C3F1/NCTR

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Test Compound: Urethane + ethanol (combination)

CAS Number: URETHCOMB

Date Report Requested: 10/18/2014

Time Report Requested: 00:10:39

First Dose M/F: NA / NA

Lab: NCTR

B6C3F1/NCTR Mouse FEMALE	2.5%ETH/30PPMUR E	2.5%ETH/90PPMUR E	5.0%ETH/0PPM URE	5.0%ETH/10PPMUR E	5.0%ETH/30PPMUR E	5.0%ETH/90PPMUR E
Lymphoma Malignant	1 (2%)	3 (6%)		1 (2%)	2 (4%)	2 (4%)
Squamous Cell Carcinoma, Metastatic, Intestine Large		1 (2%)				
ENDOCRINE SYSTEM						
Adrenal Gland	(0)	(1)	(0)	(0)	(2)	(0)
Bilateral, Subcapsular, Adenoma		1 (100%)				
Adrenal Gland, Cortex	(46)	(44)	(46)	(46)	(45)	(46)
Adenocarcinoma, Metastatic, Mammary Gland						
Adenoma					1 (2%)	
Bilateral, Adenoma						
Hemangiosarcoma						
Histiocytic Sarcoma			1 (2%)			
Lymphoma Malignant	1 (2%)	1 (2%)	1 (2%)			2 (4%)
Osteosarcoma, Metastatic, Bone	1 (2%)					
Sarcoma Stromal, Metastatic, Uterus	1 (2%)					
Sarcoma, Metastatic, Kidney		1 (2%)				
Sarcoma, Metastatic, Skin		1 (2%)				1 (2%)
Sarcoma, Metastatic, Uncertain Primary Site						
Subcapsular, Adenoma					2 (4%)	3 (7%)
Subcapsular, Carcinoma		1 (2%)		1 (2%)		
Adrenal Gland, Medulla	(45)	(41)	(44)	(44)	(38)	(46)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung					1 (3%)	
Lymphoma Malignant		1 (2%)				
Pheochromocytoma Benign						
Pheochromocytoma Malignant	1 (2%)			1 (2%)		

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 00602-05

Test Type: CHRONIC

Route: DOSED WATER

Species/Strain: Mouse/B6C3F1/NCTR

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Test Compound: Urethane + ethanol (combination)

CAS Number: URETHCOMB

Date Report Requested: 10/18/2014

Time Report Requested: 00:10:40

First Dose M/F: NA / NA

Lab: NCTR

B6C3F1/NCTR Mouse FEMALE	2.5%ETH/30PPMUR E	2.5%ETH/90PPMUR E	5.0%ETH/0PPM URE	5.0%ETH/10PPMUR E	5.0%ETH/30PPMUR E	5.0%ETH/90PPMUR E
Islets, Pancreatic	(46)	(44)	(47)	(45)	(48)	(44)
Adenoma	1 (2%)	1 (2%)		1 (2%)	3 (6%)	
Histiocytic Sarcoma					1 (2%)	
Lymphoma Malignant	2 (4%)	1 (2%)			2 (4%)	1 (2%)
Sarcoma, Metastatic, Skin				1 (2%)		
Parathyroid Gland	(37)	(31)	(35)	(41)	(41)	(36)
Lymphoma Malignant	1 (3%)					1 (3%)
Pituitary Gland	(41)	(38)	(40)	(41)	(40)	(38)
Histiocytic Sarcoma			1 (3%)			
Lymphoma Malignant		1 (3%)	1 (3%)			
Meningioma Malignant, Metastatic, Brain	1 (2%)					
Pars Distalis, Adenoma	3 (7%)	1 (3%)	6 (15%)	6 (15%)	5 (13%)	1 (3%)
Pars Distalis, Carcinoma			1 (3%)			
Thyroid Gland	(45)	(46)	(45)	(48)	(45)	(46)
Follicular Cel, Adenoma	1 (2%)		2 (4%)		1 (2%)	1 (2%)
Follicular Cel, Carcinoma						
Lymphoma Malignant						
<hr/>						
GENERAL BODY SYSTEM						
Tissue NOS	(1)	(0)	(0)	(1)	(0)	(2)
Abdominal, Histiocytic Sarcoma						1 (50%)
Abdominal, Lymphoma Malignant						
Abdominal, Sarcoma						
Histiocytic Sarcoma						
Lymphoma Malignant						
Sarcoma						
Thoracic, Alveolar/Bronchiolar Carcinoma, Metastatic, Lung				1 (100%)		

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 00602-05

Test Type: CHRONIC

Route: DOSED WATER

Species/Strain: Mouse/B6C3F1/NCTR

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Test Compound: Urethane + ethanol (combination)

CAS Number: URETHCOMB

Date Report Requested: 10/18/2014

Time Report Requested: 00:10:40

First Dose M/F: NA / NA

Lab: NCTR

B6C3F1/NCTR Mouse FEMALE	2.5%ETH/30PPMUR E	2.5%ETH/90PPMUR E	5.0%ETH/0PPM URE	5.0%ETH/10PPMUR E	5.0%ETH/30PPMUR E	5.0%ETH/90PPMUR E
GENITAL SYSTEM						
Clitoral Gland	(34)	(40)	(38)	(41)	(41)	(35)
Lymphoma Malignant						
Ovary	(47)	(48)	(46)	(47)	(46)	(45)
Adenoma, Tubular		1 (2%)			1 (2%)	2 (4%)
Cystadenoma		2 (4%)	2 (4%)	1 (2%)	3 (7%)	2 (4%)
Granulosa Cell Tumor Benign	3 (6%)	3 (6%)			5 (11%)	3 (7%)
Granulosa Cell Tumor Malignant					1 (2%)	
Hemangioma		1 (2%)			1 (2%)	
Hemangiosarcoma	1 (2%)	2 (4%)				
Histiocytic Sarcoma	1 (2%)		4 (9%)		2 (4%)	2 (4%)
Luteoma						
Lymphoma Malignant	4 (9%)	3 (6%)		1 (2%)	5 (11%)	2 (4%)
Sarcoma Stromal, Metastatic, Uterus						1 (2%)
Sarcoma, Metastatic, Skin				1 (2%)		1 (2%)
Teratoma Malignant				1 (2%)		
Thecoma Benign		1 (2%)				
Uterus	(48)	(48)	(48)	(48)	(47)	(45)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung					1 (2%)	
Endometrium, Adenoma				1 (2%)		
Hemangioma	1 (2%)	3 (6%)		1 (2%)	2 (4%)	1 (2%)
Hemangiosarcoma	1 (2%)	1 (2%)		2 (4%)	1 (2%)	1 (2%)
Histiocytic Sarcoma	2 (4%)		3 (6%)		1 (2%)	1 (2%)
Leiomyoma					2 (4%)	
Leiomyosarcoma		1 (2%)				
Lymphoma Malignant	2 (4%)	1 (2%)			1 (2%)	
Polyp Stromal	1 (2%)		2 (4%)	1 (2%)		

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 00602-05

Test Type: CHRONIC

Route: DOSED WATER

Species/Strain: Mouse/B6C3F1/NCTR

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Test Compound: Urethane + ethanol (combination)

CAS Number: URETHCOMB

Date Report Requested: 10/18/2014

Time Report Requested: 00:10:40

First Dose M/F: NA / NA

Lab: NCTR

B6C3F1/NCTR Mouse FEMALE	2.5%ETH/30PPMUR E	2.5%ETH/90PPMUR E	5.0%ETH/0PPM URE	5.0%ETH/10PPMUR E	5.0%ETH/30PPMUR E	5.0%ETH/90PPMUR E
Sarcoma		1 (2%)				
Sarcoma Stromal	1 (2%)	1 (2%)			1 (2%)	2 (4%)
Sarcoma, Metastatic, Skin		1 (2%)				1 (2%)
Vagina	(47)	(47)	(48)	(48)	(46)	(44)
Basosquamous Tumor Benign						
Hemangioma		1 (2%)				
Histiocytic Sarcoma			1 (2%)			
Leiomyosarcoma, Metastatic, Uterus						
Lymphoma Malignant		1 (2%)			2 (4%)	1 (2%)
Sarcoma Stromal, Metastatic, Uterus	1 (2%)				1 (2%)	
Sarcoma, Metastatic, Skin				1 (2%)		
Sarcoma, Metastatic, Uterus		1 (2%)				
Squamous Cell Carcinoma					1 (2%)	
Squamous Cell Papilloma						
HEMATOPOIETIC SYSTEM						
Bone Marrow	(48)	(48)	(48)	(46)	(48)	(47)
Hemangiosarcoma		1 (2%)				
Histiocytic Sarcoma	1 (2%)		2 (4%)		1 (2%)	1 (2%)
Lymphoma Malignant		1 (2%)			1 (2%)	1 (2%)
Lymph Node	(11)	(11)	(3)	(4)	(16)	(7)
Axillary, Lymphoma Malignant		1 (9%)			1 (6%)	
Axillary, Sarcoma, Metastatic, Skin			1 (33%)	1 (25%)		
Hemal, Lymphoma Malignant	1 (9%)					
Iliac, Histiocytic Sarcoma		1 (9%)				
Iliac, Lymphoma Malignant					1 (6%)	
Inguinal, Histiocytic Sarcoma						
Inguinal, Lymphoma Malignant					4 (25%)	

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 00602-05

Test Type: CHRONIC

Route: DOSED WATER

Species/Strain: Mouse/B6C3F1/NCTR

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Test Compound: Urethane + ethanol (combination)

CAS Number: URETHCOMB

Date Report Requested: 10/18/2014

Time Report Requested: 00:10:40

First Dose M/F: NA / NA

Lab: NCTR

B6C3F1/NCTR Mouse FEMALE	2.5%ETH/30PPMUR E	2.5%ETH/90PPMUR E	5.0%ETH/0PPM URE	5.0%ETH/10PPMUR E	5.0%ETH/30PPMUR E	5.0%ETH/90PPMUR E
Inguinal, Sarcoma, Metastatic, Skin		1 (9%)				
Lumbar, Alveolar/Bronchiolar Carcinoma, Metastatic, Lung					1 (6%)	
Lumbar, Histiocytic Sarcoma	1 (9%)	1 (9%)	1 (33%)			1 (14%)
Lumbar, Lymphoma Malignant	2 (18%)	2 (18%)	1 (33%)	1 (25%)	5 (31%)	1 (14%)
Lumbar, Sarcoma Stromal, Metastatic, Uterus	1 (9%)					
Lumbar, Sarcoma, Metastatic, Skin		1 (9%)		1 (25%)		
Pancreatic, Histiocytic Sarcoma		1 (9%)				
Pancreatic, Lymphoma Malignant						
Renal, Histiocytic Sarcoma		1 (9%)				1 (14%)
Renal, Leiomyosarcoma, Metastatic, Uterus						
Renal, Lymphangioma						
Renal, Lymphoma Malignant	3 (27%)	2 (18%)	1 (33%)	1 (25%)	4 (25%)	1 (14%)
Renal, Sarcoma Stromal, Metastatic, Uterus	1 (9%)				1 (6%)	1 (14%)
Renal, Sarcoma, Metastatic, Skin				1 (25%)		
Thoracic, Lymphoma Malignant	2 (18%)				1 (6%)	1 (14%)
Thoracic, Sarcoma Stromal, Metastatic, Uterus	1 (9%)					
Lymph Node, Mandibular	(43)	(46)	(48)	(46)	(38)	(47)
Adenocarcinoma, Metastatic, Uncertain Primary Site						
Histiocytic Sarcoma	1 (2%)	1 (2%)	2 (4%)			
Lymphoma Malignant	6 (14%)	4 (9%)	2 (4%)	3 (7%)	9 (24%)	2 (4%)
Mast Cell Tumor Malignant				1 (2%)		1 (2%)
Lymph Node, Mesenteric	(42)	(38)	(45)	(42)	(43)	(38)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung						1 (3%)
Histiocytic Sarcoma	1 (2%)	2 (5%)	4 (9%)		3 (7%)	2 (5%)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 00602-05

Test Type: CHRONIC

Route: DOSED WATER

Species/Strain: Mouse/B6C3F1/NCTR

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Test Compound: Urethane + ethanol (combination)

CAS Number: URETHCOMB

Date Report Requested: 10/18/2014

Time Report Requested: 00:10:40

First Dose M/F: NA / NA

Lab: NCTR

B6C3F1/NCTR Mouse FEMALE	2.5%ETH/30PPMUR E	2.5%ETH/90PPMUR E	5.0%ETH/0PPM URE	5.0%ETH/10PPMUR E	5.0%ETH/30PPMUR E	5.0%ETH/90PPMUR E
Leiomyosarcoma, Metastatic, Uterus						
Lymphoma Malignant	8 (19%)	2 (5%)	4 (9%)	5 (12%)	10 (23%)	4 (11%)
Mast Cell Tumor Malignant				1 (2%)		
Sarcoma						
Sarcoma Stromal, Metastatic, Uterus	1 (2%)				1 (2%)	1 (3%)
Sarcoma, Metastatic, Kidney		1 (3%)				
Sarcoma, Metastatic, Skin						1 (3%)
Sarcoma, Metastatic, Uncertain Primary Site						
Spleen	(46)	(46)	(48)	(47)	(48)	(45)
Hemangioma					1 (2%)	
Hemangiosarcoma		3 (7%)		1 (2%)		1 (2%)
Histiocytic Sarcoma	1 (2%)	2 (4%)	4 (8%)		3 (6%)	2 (4%)
Leiomyosarcoma, Metastatic, Uterus						
Lymphoma Malignant	8 (17%)	3 (7%)	3 (6%)	4 (9%)	9 (19%)	6 (13%)
Mast Cell Tumor Malignant				1 (2%)		
Sarcoma Stromal, Metastatic, Uterus	1 (2%)				1 (2%)	
Sarcoma, Metastatic, Lymph Node						
Sarcoma, Metastatic, Skin				2 (4%)		1 (2%)
Thymus	(34)	(36)	(39)	(38)	(43)	(39)
Adenocarcinoma, Metastatic, Mammary Gland						1 (3%)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung	1 (3%)	2 (6%)			1 (2%)	3 (8%)
Histiocytic Sarcoma	1 (3%)		2 (5%)			2 (5%)
Leiomyosarcoma, Metastatic, Uterus						
Lymphoma Malignant	7 (21%)	5 (14%)	2 (5%)	1 (3%)	11 (26%)	6 (15%)
Sarcoma, Metastatic, Kidney		1 (3%)				
Sarcoma, Metastatic, Skin				1 (3%)		1 (3%)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 00602-05

Test Type: CHRONIC

Route: DOSED WATER

Species/Strain: Mouse/B6C3F1/NCTR

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Test Compound: Urethane + ethanol (combination)

CAS Number: URETHCOMB

Date Report Requested: 10/18/2014

Time Report Requested: 00:10:40

First Dose M/F: NA / NA

Lab: NCTR

B6C3F1/NCTR Mouse FEMALE	2.5%ETH/30PPMUR E	2.5%ETH/90PPMUR E	5.0%ETH/0PPM URE	5.0%ETH/10PPMUR E	5.0%ETH/30PPMUR E	5.0%ETH/90PPMUR E
Sarcoma, Metastatic, Uncertain Primary Site						
INTEGUMENTARY SYSTEM						
Mammary Gland	(48)	(47)	(47)	(48)	(48)	(45)
Adenoacanthoma	2 (4%)	3 (6%)			1 (2%)	9 (20%)
Adenocarcinoma	11 (23%)	14 (30%)	3 (6%)	4 (8%)	6 (13%)	15 (33%)
Adenoma						
Basosquamous Tumor Malignant						
Fibroadenoma						
Lymphatic, Mast Cell Tumor Malignant						1 (2%)
Lymphoma Malignant		1 (2%)			1 (2%)	1 (2%)
Sarcoma, Metastatic, Skin						
Skin	(48)	(47)	(48)	(48)	(48)	(47)
Basal Cell Carcinoma						
Basosquamous Tumor Malignant						
Fibroma		1 (2%)				
Fibrous Histiocytoma						
Hemangioma	1 (2%)					
Hemangiosarcoma		2 (4%)				
Lymphoma Malignant					1 (2%)	
Osteosarcoma	1 (2%)		1 (2%)			
Papilloma						
Sarcoma	6 (13%)	5 (11%)	3 (6%)	7 (15%)	4 (8%)	7 (15%)
Squamous Cell Carcinoma, Metastatic, Intestine Large		1 (2%)				
MUSCULOSKELETAL SYSTEM						
Bone	(48)	(48)	(48)	(48)	(48)	(47)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 00602-05

Test Type: CHRONIC

Route: DOSED WATER

Species/Strain: Mouse/B6C3F1/NCTR

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Test Compound: Urethane + ethanol (combination)

CAS Number: URETHCOMB

Date Report Requested: 10/18/2014

Time Report Requested: 00:10:40

First Dose M/F: NA / NA

Lab: NCTR

B6C3F1/NCTR Mouse FEMALE	2.5%ETH/30PPMUR E	2.5%ETH/90PPMUR E	5.0%ETH/0PPM URE	5.0%ETH/10PPMUR E	5.0%ETH/30PPMUR E	5.0%ETH/90PPMUR E
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung						1 (2%)
Femur, Hemangioma						
Femur, Hemangiosarcoma		1 (2%)				
Femur, Lymphoma Malignant		1 (2%)				1 (2%)
Femur, Sarcoma, Metastatic, Skin	1 (2%)					
Humerus, Osteosarcoma	1 (2%)					
Rib, Osteosarcoma	1 (2%)					
Rib, Right, Osteosarcoma						
Right, Osteosarcoma						
Sternum, Lymphoma Malignant		1 (2%)				1 (2%)
Sternum, Sarcoma						
Sternum, Sarcoma, Metastatic, Skin						
Vertebra, Osteosarcoma	1 (2%)					
Skeletal Muscle	(48)	(48)	(48)	(48)	(48)	(47)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung		1 (2%)				
Diaphragm, Adenocarcinoma, Metastatic, Mammary Gland						1 (2%)
Diaphragm, Alveolar/Bronchiolar Carcinoma, Metastatic, Lung						1 (2%)
Diaphragm, Sarcoma, Metastatic, Skin						
Diaphragm, Teratoma Malignant, Metastatic, Ovary				1 (2%)		
Hemangiosarcoma		1 (2%)				
Lymphoma Malignant	1 (2%)	1 (2%)			4 (8%)	
Mast Cell Tumor Malignant				1 (2%)		
Rhabdomyosarcoma						
Sarcoma						2 (4%)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 00602-05

Test Type: CHRONIC

Route: DOSED WATER

Species/Strain: Mouse/B6C3F1/NCTR

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Test Compound: Urethane + ethanol (combination)

CAS Number: URETHCOMB

Date Report Requested: 10/18/2014

Time Report Requested: 00:10:41

First Dose M/F: NA / NA

Lab: NCTR

B6C3F1/NCTR Mouse FEMALE	2.5%ETH/30PPMUR E	2.5%ETH/90PPMUR E	5.0%ETH/0PPM URE	5.0%ETH/10PPMUR E	5.0%ETH/30PPMUR E	5.0%ETH/90PPMUR E
Sarcoma, Metastatic, Skin		1 (2%)		1 (2%)		1 (2%)
Sarcoma, Metastatic, Uncertain Primary Site						
NERVOUS SYSTEM						
Brain	(0)	(0)	(0)	(0)	(4)	(0)
Brain, Brain Stem	(0)	(0)	(0)	(0)	(1)	(0)
Brain, Cerebellum	(47)	(48)	(48)	(48)	(40)	(47)
Lymphoma Malignant		1 (2%)				
Brain, Cerebrum	(47)	(48)	(48)	(48)	(44)	(47)
Carcinoma, Deep Invasion			1 (2%)			
Lymphoma Malignant		1 (2%)				2 (4%)
Meningioma Malignant	1 (2%)					
Peripheral Nerve	(48)	(48)	(48)	(48)	(48)	(47)
Lymphoma Malignant						
Spinal Cord	(0)	(0)	(0)	(0)	(8)	(0)
Spinal Cord, Thoracic	(47)	(48)	(48)	(48)	(40)	(47)
Lymphoma Malignant		1 (2%)				
RESPIRATORY SYSTEM						
Larynx	(47)	(46)	(45)	(47)	(47)	(47)
Lymphoma Malignant						
Lung	(48)	(48)	(48)	(48)	(48)	(48)
Adenoacanthoma, Metastatic, Mammary Gland						1 (2%)
Adenocarcinoma, Metastatic, Mammary Gland	1 (2%)			1 (2%)		1 (2%)
Adenocarcinoma, Multiple, Metastatic, Mammary Gland						
Alveolar/Bronchiolar Adenoma	12 (25%)	10 (21%)	4 (8%)	8 (17%)	15 (31%)	8 (17%)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 00602-05

Test Type: CHRONIC

Route: DOSED WATER

Species/Strain: Mouse/B6C3F1/NCTR

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Test Compound: Urethane + ethanol (combination)

CAS Number: URETHCOMB

Date Report Requested: 10/18/2014

Time Report Requested: 00:10:41

First Dose M/F: NA / NA

Lab: NCTR

B6C3F1/NCTR Mouse FEMALE	2.5%ETH/30PPMUR E	2.5%ETH/90PPMUR E	5.0%ETH/0PPM URE	5.0%ETH/10PPMUR E	5.0%ETH/30PPMUR E	5.0%ETH/90PPMUR E
Alveolar/Bronchiolar Adenoma, Multiple	4 (8%)	18 (38%)	1 (2%)	2 (4%)	3 (6%)	22 (46%)
Alveolar/Bronchiolar Carcinoma	4 (8%)	11 (23%)	1 (2%)	5 (10%)	7 (15%)	8 (17%)
Alveolar/Bronchiolar Carcinoma, Multiple	2 (4%)	12 (25%)		2 (4%)	2 (4%)	15 (31%)
Basal Cell Carcinoma, Metastatic, Skin						
Basosquamous Tumor Malignant, Metastatic, Mammary Gland						
Basosquamous Tumor Malignant, Metastatic, Zymbal'S Gland						
Carcinoma, Metastatic, Harderian Gland						
Carcinoma, Metastatic, Mammary Gland	1 (2%)					1 (2%)
Carcinoma, Metastatic, Zymbal'S Gland						
Granulosa Cell Tumor Malignant, Metastatic, Ovary					1 (2%)	
Hemangiosarcoma						
Hepatocellular Carcinoma, Metastatic, Liver	1 (2%)				1 (2%)	
Histiocytic Sarcoma	1 (2%)	1 (2%)	4 (8%)		3 (6%)	1 (2%)
Leukemia				1 (2%)		
Lymphoma Malignant	3 (6%)	5 (10%)	1 (2%)	1 (2%)	5 (10%)	4 (8%)
Osteosarcoma, Metastatic, Bone	1 (2%)					
Osteosarcoma, Metastatic, Skin			1 (2%)			
Sarcoma Stromal, Metastatic, Uterus		1 (2%)				
Sarcoma, Metastatic, Skin	1 (2%)	3 (6%)	1 (2%)	4 (8%)		3 (6%)
Sarcoma, Metastatic, Uncertain Primary Site						1 (2%)
Squamous Cell Carcinoma, Metastatic, Intestine Large		1 (2%)				
Nose	(48)	(48)	(47)	(48)	(48)	(47)
Carcinoma, Metastatic, Harderian Gland						1 (2%)
Lymphoma Malignant		1 (2%)				

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 00602-05

Test Type: CHRONIC

Route: DOSED WATER

Species/Strain: Mouse/B6C3F1/NCTR

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Test Compound: Urethane + ethanol (combination)

CAS Number: URETHCOMB

Date Report Requested: 10/18/2014

Time Report Requested: 00:10:41

First Dose M/F: NA / NA

Lab: NCTR

B6C3F1/NCTR Mouse FEMALE	2.5%ETH/30PPMUR E	2.5%ETH/90PPMUR E	5.0%ETH/0PPM URE	5.0%ETH/10PPMUR E	5.0%ETH/30PPMUR E	5.0%ETH/90PPMUR E
Trachea	(46)	(47)	(47)	(48)	(47)	(45)
SPECIAL SENSES SYSTEM						
Ear	(0)	(0)	(0)	(0)	(1)	(0)
Squamous Cell Papilloma					1 (100%)	
Eye	(48)	(46)	(48)	(48)	(47)	(45)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung						1 (2%)
Lymphoma Malignant		1 (2%)				
Harderian Gland	(46)	(47)	(48)	(48)	(46)	(46)
Adenoma	9 (20%)	16 (34%)	4 (8%)	7 (15%)	6 (13%)	14 (30%)
Bilateral, Adenoma		3 (6%)				6 (13%)
Bilateral, Carcinoma		4 (9%)		1 (2%)	1 (2%)	
Carcinoma	6 (13%)	12 (26%)	1 (2%)	10 (21%)	6 (13%)	10 (22%)
Histiocytic Sarcoma			1 (2%)			
Lymphoma Malignant	1 (2%)	1 (2%)			3 (7%)	
Lacrimal Gland	(44)	(43)	(45)	(45)	(45)	(43)
Histiocytic Sarcoma			1 (2%)			
Lymphoma Malignant	1 (2%)	1 (2%)			3 (7%)	1 (2%)
Mast Cell Tumor Malignant				1 (2%)		
Zymbal's Gland	(41)	(44)	(48)	(46)	(43)	(40)
Basosquamous Tumor Malignant						
Carcinoma						
Lymphoma Malignant		1 (2%)				
URINARY SYSTEM						
Kidney	(48)	(48)	(48)	(48)	(48)	(47)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung						1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 00602-05

Test Type: CHRONIC

Route: DOSED WATER

Species/Strain: Mouse/B6C3F1/NCTR

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Test Compound: Urethane + ethanol (combination)

CAS Number: URETHCOMB

Date Report Requested: 10/18/2014

Time Report Requested: 00:10:41

First Dose M/F: NA / NA

Lab: NCTR

B6C3F1/NCTR Mouse FEMALE	2.5%ETH/30PPMUR E	2.5%ETH/90PPMUR E	5.0%ETH/0PPM URE	5.0%ETH/10PPMUR E	5.0%ETH/30PPMUR E	5.0%ETH/90PPMUR E
Hemangiosarcoma		2 (4%)				1 (2%)
Histiocytic Sarcoma			1 (2%)			1 (2%)
Lymphoma Malignant	3 (6%)	3 (6%)	2 (4%)		5 (10%)	3 (6%)
Mast Cell Tumor Malignant				1 (2%)		1 (2%)
Osteosarcoma, Metastatic, Bone	1 (2%)					
Osteosarcoma, Metastatic, Skin			1 (2%)			
Perirenal Tiss, Hemangiosarcoma		1 (2%)				
Sarcoma		1 (2%)				
Sarcoma, Metastatic, Skin	1 (2%)			2 (4%)		
Urinary Bladder	(47)	(45)	(46)	(46)	(47)	(45)
Histiocytic Sarcoma			1 (2%)			
Leiomyosarcoma, Metastatic, Uterus						
Lymphoma Malignant	3 (6%)	1 (2%)	1 (2%)		4 (9%)	
SYSTEMIC LESIONS						
Multiple Organ	*(48)	*(48)	*(48)	*(48)	*(48)	*(48)
Histiocytic Sarcoma	3 (6%)	2 (4%)	4 (8%)		3 (6%)	2 (4%)
Leukemia				1 (2%)		
Lymphoma Malignant	11 (23%)	6 (13%)	5 (10%)	6 (13%)	15 (31%)	10 (21%)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 00602-05
Test Type: CHRONIC
Route: DOSED WATER
Species/Strain: Mouse/B6C3F1/NCTR

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)
Test Compound: Urethane + ethanol (combination)
CAS Number: URETHCOMB

Date Report Requested: 10/18/2014
Time Report Requested: 00:10:41
First Dose M/F: NA / NA
Lab: NCTR

B6C3F1/NCTR Mouse FEMALE	0% ETH/ 0PPM URE	0% ETH/ 10PPMURE	0% ETH/ 30PPMURE	0% ETH/ 90PPMURE	2.5%ETH/0PPM URE	2.5%ETH/10PPMUR E
Tumor Summary for FEMALE						
Total Animals with Primary Neoplasms (b)	37	35	45	47	29	33
Total Primary Neoplasms	55	64	118	195	47	59
Total Animals with Benign Neoplasms	22	26	38	42	21	21
Total Benign Neoplasms	27	39	65	88	28	30
Total Animals with Malignant Neoplasms	26	20	37	46	14	22
Total Malignant Neoplasms	28	25	53	107	19	29
Total Animals with Metastatic Neoplasms	1	2	4	20	1	2
Total Metastatic Neoplasms	2	2	17	35	2	3
Total Animals with Malignant Neoplasms Uncertain Primary Site				2		
Total Animals with Neoplasms Uncertain - Benign or Malignant						
Total Uncertain Neoplasms						

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 00602-05
Test Type: CHRONIC
Route: DOSED WATER
Species/Strain: Mouse/B6C3F1/NCTR

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)
Test Compound: Urethane + ethanol (combination)
CAS Number: URETHCOMB

Date Report Requested: 10/18/2014
Time Report Requested: 00:10:41
First Dose M/F: NA / NA
Lab: NCTR

B6C3F1/NCTR Mouse FEMALE	2.5%ETH/30PPMUR E	2.5%ETH/90PPMUR E	5.0%ETH/0PPM URE	5.0%ETH/10PPMUR E	5.0%ETH/30PPMUR E	5.0%ETH/90PPMUR E
Tumor Summary for FEMALE						
Total Animals with Primary Neoplasms (b)	45	48	32	43	47	47
Total Primary Neoplasms	108	188	47	90	121	182
Total Animals with Benign Neoplasms	31	39	22	26	37	41
Total Benign Neoplasms	51	86	27	37	72	80
Total Animals with Malignant Neoplasms	38	45	17	35	37	46
Total Malignant Neoplasms	57	102	20	53	49	102
Total Animals with Metastatic Neoplasms	10	10	3	8	4	12
Total Metastatic Neoplasms	26	25	4	23	13	35
Total Animals with Malignant Neoplasms Uncertain Primary Site						1
Total Animals with Neoplasms Uncertain - Benign or Malignant						
Total Uncertain Neoplasms						

** END OF REPORT **

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically